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Preface 
 
 
Crystals of the same molecule can be in multiple forms. Phenomena of polymorphism, 
solvate formation, and co-crystallization affect solubility, dissolution rate, and other 
physicochemical properties. Therefore, characterization and identification of multiple 
forms of crystals are one of the most popular topics in modern solid state chemistry. 
Chirality is significant issue especially in pharmaceutical industry because many 
pharmaceutical compounds have chirality and several chiral drugs have different 
pharmacological effects between their enantiomers. In some cases, one enantiomer 
causes beneficial effect and yet the other harmful effect. 
Thalidomide, one of chiral compounds, was marketed as a safe sedative and 
hypnotic drug in 1956. Before long, its side-effect of teratogenicity caused tragic drug 
disaster and thalidomide was withdrawn from market in 1962. Recently, however, its 
potential as a treatment for intractable diseases, such as erythema nodosum leplosum 
and multiple myeloma, has been revealed and thus thalidomide has attracted 
considerable attention again. 
Although a number of researches have reported the bioactivity of thalidomide, 
only a few researches have reported its physicochemical properties. For instance, 
racemic thalidomide is known to exhibits lower solubility and higher melting point 
than the enantiomeric thalidomide. However, the origin of differences in these 
physicochemical properties between enantiomeric and racemic thalidomides has not 
been investigated. Although the knowledge about the crystal structure is essential for 
understanding these physicochemical properties, the crystal structure of enantiomeric 
thalidomide has not been published for about 40 years since that of racemic 
thalidomide was reported in 1971. 
The objectives of this thesis are to evaluate methods for crystallization of 
thalidomide, to determine crystal structure and absolute configuration of enantiomeric 
thalidomide, and to investigate the origin of differences in physicochemical properties 
between enantiomeric and racemic thalidomides. 
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This thesis is composed of following five chapters. 
 
Chapter 1 provides the general introduction of this thesis. As to crystal, chirality, and 
thalidomide, this chapter introduces the fundamental aspects such as definitions of 
terms, historical backgrounds, and significant properties. 
 
Chapter 2 evaluates methods for crystallization of thalidomide. The crystallization 
methods are determined with consideration of possible multiple forms of thalidomide 
crystal and undesirable chiral inversion in crystallization of enantiomeric thalidomide. 
 
Chapter 3 determines crystal structure of (S)-thalidomide with single crystal X-ray 
diffractometry. Hydrogen bonded dimers structure in unsolvate and infinite hydrogen 
bonded chains structure in solvate are investigated in detail. 
 
Chapter 4 investigates the origin of differences in physicochemical properties between 
enantiomeric and racemic thalidomides. Crystal structures of (S)- and 
(RS)-thalidomides are compared and structural stabilities of dimers in each crystal are 
evaluated by theoretical calculations. 
 
Chapter 5 concludes this thesis with future prospects. 
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1. General introduction 
 
 
 
1.1 Multiple forms of crystal 
 
Crystal is a solid substance formed with orderly arranged units. These units generally 
consist of atoms or molecules. In the case of molecules, the crystals are especially 
called molecular crystals. Studies concerning crystal are called crystallography. The 
primary significance of the crystallography is investigations into crystal structures. The 
crystal structures are usually determined with X-ray diffractometry based on the 
property of orderly arrangements in crystals. Determinations of crystal structures 
provide valuable information of the substances. The principal information obtainable 
from X-ray diffractometry on molecular crystals is details of component molecules, 
such as those conformations and relative position to another molecule. Thus, 
determinations of crystal structures are useful for understanding the physicochemical 
properties of the substances. 
Crystal structure is fundamental knowledge of a substance. However, crystal 
structure of a substance is not unique in a particular form. In other words, crystal 
structures of a substance obtained from various crystallization methods are not always 
correspond with each others. This phenomenon of the same component molecules 
being in different arrangements is called polymorphism (Figure 1.1). Polymorphic 
forms are generally distinguished by prefixes. Although the number of possible 
polymorphs is limited because crystalline solid is highly stable state, differences in 
crystal structures of polymorphs results in different physicochemical properties of each 
polymorph. Therefore, controlling polymorphism is a significant issue in crystal 
engineering.  
Moreover, molecules of some compounds often crystallized with those of other 
compound. This phenomenon is called co-crystallization in the general meaning. In the 
case of crystallization from solution, solute molecules often form solvates: crystals 
including solvent molecules as guests. Solvates are often regarded as a particular case 
of co-crystals. Nevertheless, the discrimination of solvate and co-crystal has been in 
controversy. Physicochemical properties of solvates are also different from those of 
unsolvated polymorphs.  
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Thus, crystals of the same molecule can be in multiple forms. Phenomena of 
polymorphism, solvate formation, and co-crystallization affect solubility, dissolution 
rate, and other physicochemical properties. Therefore, characterization and 
identification of multiple forms of crystals are one of the most popular topics in 
modern solid state chemistry. [1-8]  
 
 
 
 
 
 
  
Figure 1.1 Multiple forms of molecular crystal. 
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1.2 Definition of chirality and trends in chiral drug development 
 
Chirality is a property of an object to be non-superimposable on its mirror image, and 
the term “chiral” means having chirality. The term “achiral” means not chiral, i.e. 
being identical to its mirror image. Most universal example of chiral object is human 
hands: one hand is never superimposed on the other hand (Figure 1.2) [9, 10]. 
In the case of molecular structure, an atom with 4 different functional groups has 
chirality, and this is called molecular chirality (Figure 1.3). Two configurational 
isomers of chiral molecules are distinguished as (R)-isomer or (S)-isomer. Each of 
these two configurational isomers is called enantiomer. In chirality-independent 
physicochemical phenomena, one enantiomer exhibits same properties with the other. 
The mixture of enantiomers in same amount is called racemate. Generally, the term 
“racemate” is used in the same meaning with racemic mixture, which is different from 
racemic compound. 
 
 
 
 
  
Figure 1.2 “human intelligence, a left and a right hand and two enantiomorphous tetrahedral” 
drawn by Hans Erni. This artwork was the commemorative gift to Vladimir Prelog, winner of 
the 1975 Novel Prize in chemistry for his research into the stereochemistry of organic 
molecules and reactions [9, 10]. 
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The history of chirality started from two centuries ago. Jean-Baptiste Biot first 
observed the optical activity in 1815. The optical activity is a phenomenon based on 
molecular chirality that a solution of enantiomer rotates the plane of the incident 
polarized light. Louis Pasteur deduced that the origin of the optical activity is molecular 
structure. He achieved the mechanical separation of tartrate enantiomers in 1848. 
However, he coined the chiral structural arrangement in molecules as “dissymmetry”. 
The term “chirality” itself originated from Lord Kelvin‟s coinage: “I call any 
geometrical figure or group of points, chiral, and say that it has chirality, if its image in 
a plane mirror, ideally realized, cannot be brought to coincide with itself. Two equal and 
similar right hands are homochirally similar. Equal and similar right and left hands are 
heterochirally similar or allochirally similar (but heterochirally is better). These are 
also called enantiomorphs, after a usage introduced, I believe, by German writers. Any 
chiral object and its image in a plane mirror are heterochirally similar.” [11]. 
 
 
 
 
 
  
Figure 1.3 Configurational isomers of chiral molecule. 
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Chirality is significant issue especially in pharmaceutical industry because many 
pharmaceutical compounds have chirality and this fact cause undesirable problems. 
Several chiral drugs have different pharmacological effects between their enantiomers. 
In some cases, one enantiomer causes beneficial effect and yet the other harmful effect. 
This is mainly because protein, those receptor, homochirally consist of L-amino acids. 
Therefore, doses of chiral drug as racemate require careful attention. 
 In 1992, the US Food and Drug Administration (FDA) established the guideline 
for the development of chiral drugs [12]. Since then, the increasing number of chiral 
drugs has been developed as single enantiomer drugs. The distribution of 
worldwide-approved drugs concerning chirality is as follows: the ratio of single 
enantiomers is 39%, that of racemates is 23%, and that of achirals is 38%, respectively 
(Figure 1.4) [13]. 
 
 
 
 
 
 
 
  
 
Figure 1.4 (a) Distribution of worldwide-approved drugs according to chirality character in the 
period 1983–2002 (b) Distribution of FDA approved drugs according to chirality character in 
the period 1991–2002 [13].  
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Determining absolute configurations [14] of chiral molecules are significant issues 
because of possible difference in physicochemical properties between enantiomers. 
There are two methods for non-empirically determining absolute configurations of 
chiral molecules. One is single crystal X-ray diffractometry with the Bijvoet method 
[15] and the other is circular dichroic exciton chirality method [16]. 
In the case of compounds of which single crystals are obtainable, single crystal 
X-ray diffractometry becomes the most established method. Bijvoet method in X-ray 
diffractometry is capable of determining absolute configurations of chiral molecules 
based on anomalous dispersion, a phenomenon of occurring dispersed X-ray by 
resonance. However, determining absolute configurations of molecules composed with 
only light atoms is difficult due to too small effect of this dispersion. Nevertheless, it 
has been becoming easier because technological progress has increased available 
intensity of X-ray and accuracy of diffraction data.  
On the other hand, circular dichroic exciton chirality method requires no 
crystallization and has an advantage on compounds of which crystals are unobtainable 
or unstable. However, this method has difficulty in correctly understanding the results. 
 
 
1.3 Historical background of thalidomide 
 
3‟-(N-phthalimide)glutarimide, thalidomide (Figure 1.5) is a chiral compound 
consisting of phthalimide ring and glutarimide ring. Thalidomide is most frequently 
mentioned as an example of chiral molecule because of its history. This section 
reviews the historical background of thalidomide in the following three subsections. 
Section 1.3.1 introduces the history of thalidomide, section 1.3.2 researches on the 
teratogenicity, section 1.3.3 undesirable property of chiral inversion. 
 
 
1.3.1 Revival of dark remedy 
 
Thalidomide was first synthesized by CIBA pharmaceutical company in 1953 and was 
first marketed as a safe sedative and hypnotic drug as the name of Contergan
®
 by 
Chemie Grünenthal in 1956 [17]. Since then, the number of babies boned with limb 
defect had been increased. McBride, in 1961 [18], and Lenz, in 1962 [19], reported 
that this teratogenic effect is caused by pregnant women taking thalidomide, and then 
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thalidomide was withdrawn from market in 1962. This drug disaster caused by 
side-effect of thalidomide is called “thalidomide tragedy”. The number of worldwide 
victims is estimated to be over 10,000 [20].  
However, anti-inflammatory effect of thalidomide was reported in 1965 [21], and 
thalidomide was approved as a treatment of erythema nodosum leprosum by the FDA 
and has been marketed as the name of THALOMID
®
 by Celgene Corporation under 
the strict control since 1998. Furthermore, its potential of anti-angiogenesis activity 
was revealed in 1994 [22], and antitumor effect based on this activity was confirmed in 
1999 [23]. Currently, thalidomide has been approved as a treatment of multiple 
myeloma in about 20 countries since the first approved in Australia in 2003 (Table 1.1) 
[24]. In Japan, thalidomide has been marketed as the name of THALED
®
 Capsule 100 
by Fujimoto Pharmaceutical Corporation since 2009. Other beneficial potentials of 
thalidomide for intractable diseases, such as behcet's disease, pyoderma gangrenosum, 
and rheumatologic arthritis, are also reported [25-28], and some of them are in clinical 
testing. The number of research papers concerning thalidomide is shown in Figure 1.6. 
This data were obtained by searching the word “thalidomide” through all type 
documents in each year using Web of Science
®
. Thus thalidomide has attracted 
considerable attention again. 
 
 
 
 
 
Figure 1.5 Structural formula of thalidomide (*: chiral center). 
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Approval Date Country 
2003/10 Australia 
2003/12 New Zealand 
2004/ 5 Turk 
2004/ 8 Israel 
2006/ 4 South Korea 
2006/ 5 USA 
2006/ 6 Thailand 
2007/10 South Africa 
2008/ 4 EU 
2008/10 Japan 
Figure 1.6 The number of research papers concerning thalidomide. 
Table 1.1 The countries where thalidomide was 
approved as a treatment of multiple myeloma [24]. 
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1.3.2 Controversy over teratogenicity 
 
After the thalidomide tragedy, a number of researches, as a matter of course, have 
investigated the teratogenicity of thalidomide. However, the mechanism of its 
teratogenicity had been unclear for a long period, although influence of 
anti-angiogenesis activity [29, 30] and damage of DNA by oxidation [31] had been 
proposed as possible causes. Revelation of the mechanism of thalidomide teratogenicity 
is extremely difficult because metabolism and hydrolysis of thalidomide progressed in 
human body, and result in the existence of enormous number of products.  
More recently, Handa et al. identified a protein cereblon as a primary target of 
thalidomide teratogenicity [32]. They immobilized thalidomide derivatives to 
ferrite-glycidyl methacrylate beads. These beads were incubated in human HeLa cell 
extracts. As a result, protein specifically interacted with these beads was identified as 
cereblon. Cereblon is revealed to be a subunit of a functional E3 ubiquitin ligase 
complex. Thalidomide teratogenicity was indicated to arise from inhibition of the 
function of this E3 ubiquitin ligase. However, as they mentioned, whether thalidomide 
or one of its metabolites is actually interacted with cereblon remain unclear. In addition, 
chirality of thalidomide was not described in their study. More specifically, whether or 
not there is difference in binding behavior with cereblon between enantiomers of 
thalidomide has been unclear. 
Several researches focused on the difference in bioactivities between enantiomers 
of thalidomide. In 1979, Blaschke et al. reported that only (S)-thalidomide shows 
teratogenicity with the examinations of separately dosing enantiomers to rats and mice 
[33]. This report, as a matter of course, attracted considerable attention, and has been 
thought to trigger the present guideline for the development of chiral drugs as 
mentioned in section 1.2. However, this report has been doubted in several points. One 
of examples is employing rats and mice as the model animal because rats and mice 
strongly resist to teratogenicity. Furthermore, no difference was observed between 
enantiomers of thalidomide in a similar experiment to rabbits, showing sensitivity to 
teratogenicity [34]. 
On the contrary, Schmahl et al. examined on EM12, an analog of thalidomide with 
stronger teratogenicity, by dose of each enantiomer to marmoset monkeys [35]. As a 
result, the incidence rate of teratogenic effect in the case of (S)-EM12 was extremely 
higher than that of (R)-EM12. Although this results support the Blaschke‟s report, the 
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teratogenic effect was slightly observed in the case of (R)-EM12. To understand these 
results consistently, a phenomenon of “chiral inversion” is never negligible. 
 
 
1.3.3 Chiral inversion: cause of the confusion 
 
The chiral inversion is phenomenon that a chiral compound inverts its chirality, namely, 
one enantiomer turns into the other. Thalidomide is well-known to show this 
phenomenon of chiral inversion [36]. The chiral inversion mechanism of thalidomide 
is proposed as isomerization via base-catalyzed keto-enol tautomerism due to high 
acidity of the proton bonding to the chiral center, as shown in Figure 1.7 [37]. 
According to this mechanism, the chiral inversion will be avoidable in polar aprotic 
and nonpolar solvents. Nevertheless, thalidomide easily inverts its chirality in polar 
solution state. For instance, Hashimoto et al. reported that almost all enantiomers of 
thalidomide invert their chirality with incubation in water solution for 10 h at 37°C 
[38].  
 
 
 
 
 
 
 
 
Figure 1.7 Chiral inversion via base-catalyzed keto-enol tautomerism. 
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Moreover, this chiral inversion of thalidomide is accelerated especially in human 
body. This is because albumin, hydroxyl ions, phosphate, and amino acids catalyze the 
chiral inversion [39]. Blaschke et al. also reported that chiral inversion of thalidomide 
in human citric plasma is extremely fast: 25% of enantiomers invert their chirality with 
incubation for 10 min at 37°C [40]. Therefore, experimentally confirming the 
differences in bioactivity between the enantiomers of thalidomide is extremely difficult. 
Furthermore, the unavoidable chiral inversion in human body of thalidomide is thought 
to one of the reasons why thalidomide has been approved for sale as the racemate 
against the recent trends in the development of chiral drugs. 
 
 
1.4 Overall objectives 
 
In the case of solution state, molecules play main roll in physicochemical phenomena. 
Thus, there is no difference in chirality-independent properties between an enantiomer 
and the racemate. Whereas in the case of solid state, major differences of 
chirality-independent properties are in between an enantiomer and the racemate, not 
the enantiomeric isomers. This is because crystal structures of enantiomeric and 
racemic compounds are essentially different. Therefore, the idea of comparison 
between an enantiomer and the racemate is significant for studies concerning crystals 
of chiral compounds, particularly for pharmaceutical compounds due to recent trends 
in the chiral drug development. 
Although a number of studies have reported the bioactivity of thalidomide [20, 
26-28, 31, 34, 41], only a few studies have reported its physicochemical properties. 
Racemic thalidomide is known to exhibit lower solubility and higher melting point 
than the enantiomers [34]. It is also known that the oral absorption of racemic 
thalidomide is slower than that of the enantiomers [27, 41]. However, the origin of 
differences in these physicochemical properties between enantiomeric and racemic 
thalidomides has not been investigated. 
Crystal structures of racemic thalidomide have been investigated since 1971. Two 
polymorphs of α and β forms are known in racemic thalidomide. However, despite the 
renewed attention to thalidomide, crystal structures of enantiomeric thalidomide had 
not been reported. 
There are a few possible reasons for this. First, thalidomide has not been regarded 
as focus of research, not only crystallography but also in other fields, due to the 
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disaster. This fact is reflected in Figure 1.6. The other reason may be in asymmetric 
synthesis of enantiomeric thalidomides. Until recently, practical asymmetric synthesis 
of the enantiomeric thalidomide had not been achieved. This is because the chiral 
inversion easily occurs under high temperature and high basicity conditions for 
creating the phthalimide and glutarimide rings of thalidomide. At long last, in 2001, the 
three-step synthesis of enantiomeric thalidomide from ornithine with 99% e.e. in good 
yield was achieved. 
As to experimental difficulty, chiral inversion of thalidomide will be a problem in 
crystallization of enantiomeric thalidomides. This is because the enantiomeric isomers 
generated by chiral inversion are nothing but impurities in crystallization of 
enantiomeric thalidomides. Therefore, it requires proper consideration of 
crystallization method. Although chiral inversion of thalidomide has often been 
concerned, particularly in pharmacological study, mechanism of the chiral inversion 
has been referred in few studies. 
In addition, even if enantiomeric crystals of thalidomide were successfully 
obtained, another problem may have been in determination of absolute configuration 
with single crystal X-ray diffractometry. This is because thalidomide is composed with 
only light atoms of carbon, nitrogen, oxygen, and hydrogen. Nevertheless, determining 
absolute configuration of light molecules is becoming easier because of recent progress 
in X-ray diffractometry. 
On the above background, this study focuses on crystal structures of thalidomide. 
The objectives of this thesis are summarized as: 
･ Evaluation of methods for crystallization of thalidomide; 
･ Determination of crystal structure and absolute configuration of enantiomeric 
thalidomide; 
･ Investigation into the origin of differences in physicochemical properties between 
enantiomeric and racemic thalidomides. 
The primary significance of this study is on the idea of comparison between an 
enantiomer and the racemate. In chapter 2, methods for crystallization of thalidomide 
are evaluated with consideration of possible multiple forms. In chapter 3, detail structure 
of (S)-thalidomide crystals obtained from different methods are investigated. In chapter 
4, crystal structures of (RS)-thalidomide obtained from different methods are 
investigated and compared with those of (S)-thalidomide. 
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2. Evaluation of methods for crystallization of 
thalidomide 
 
 
 
2.1 Introduction 
 
Molecules of a compound are capable of forming different crystals depending on the 
crystallization method. This multiple formation is characterized as a phenomenon of 
polymorphism. Moreover, molecules of a compound are often crystallized with 
including solvent molecules in its crystal lattice. These crystals are called as solvates. 
This phenomenon of solvate formation also depends on the crystallization method. 
These phenomena of polymorphism and solvate formation greatly impact on solubility, 
dissolution rate, and other physicochemical properties, because of difference in crystal 
structure between polymorphs and solvates. Therefore, controlling polymorphism and 
solvate formation is significant issues, particularly in pharmaceutical industry for drug 
safety and bioavailability. 
Controlling habits of crystal is also important issue, for instance application in 
pharmaceutical preparation, although its effects on physicochemical properties are less 
than polymorphs and solvates. In some case, the habits of isomorphic crystals are 
different from each other depending on the crystallization methods. 
Thus, characterization and identification of multiple forms of crystals are one of 
the most popular topics in modern solid state chemistry. [1-8] However, absolutely 
controlling the phenomena of polymorphism and solvate formation with the present 
crystal engineering is impossible. Actually, a number of polymorphs and solvates were 
obtained as unpredictable results. Nevertheless, appropriate consideration on the 
crystallization method is capable of narrowing the possibilities for occurrences of these 
phenomena. 
Crystal structures of racemic thalidomide have been investigated since 1971. [9] 
Two polymorphs of α and β forms are known in (RS)-thalidomide. [10] However, 
crystallographical studies on enantiomeric thalidomide have not been reported. 
This study, in this chapter, evaluates methods for crystallization of thalidomide 
with consideration of possible multiple forms of thalidomide crystal and undesirable 
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chiral inversion in crystallization of enantiomeric thalidomide. The crystallization 
methods were determined on the basis of consideration for selection of solvent and 
technique for crystallization. Chiral inversions in determined methods were estimated 
with circular dichroism (CD) measurements. Habits of obtained crystals were observed 
with polarizing microscope. The possibilities of polymorphs or solvates were 
investigated with thermogravimetry-differential thermal analyses (TG-DTA). 
 
 
2.2 Determination of crystallization methods 
 
A method for crystallization is divided into two major factors: selection of solvent and 
technique for crystallization. 
The solvent for crystallization is one of most crucial factor impacting on the 
phenomena of polymorphism and solvate formation. At an early phase in crystal 
growth from solution, crystal nuclei are grew from clusters which are assembling unit 
of solute molecules. The forms of these clusters critically depend on the polarity of 
solvent: high-polar cluster form is more favorable in high-polar solvent, contrastingly, 
low-polar cluster form in low-polar solvent. Thus, crystallizations in solvents with 
different polarity often cause the formation of polymorphs and solvates. 
The most common technique for crystallization is solvent evaporation. The solvent 
evaporation technique is easy to control the condition and require no unconventional 
equipment. Therefore, solvent evaporation technique suits for the first attempt of 
crystallization. 
Water is one of the most important polar solvent, particularly for crystallizing 
pharmaceutical compound because only hydrates of solvates may be of practical use as 
drugs. Therefore, crystallization from water solution should be attempted. However, in 
the case of thalidomide, large crystals enough to conduct X-ray diffractometry are 
difficult to be obtained by crystallization from water solution due to poor solubility of 
thalidomide in water. Actually, preliminary experiment of crystallization from water 
solution with solvent evaporation technique obtained only powder, whose quality is 
impossible to be identified.  
Methanol is also common polar solvent. According to previous study on solubility 
of thalidomide, solubility of thalidomide in water is 0.238 mM at 32 °C, whereas that 
in methanol is 4.38 mM at 32 °C [11]. On this point, single crystals of more suitable 
size for X-ray diffractometry should be obtainable with crystallization with solvent 
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evaporation technique from methanol solution. Nevertheless, this solubility of 
methanol is relatively poor compared to other solvents such as after mentioned 
chloroform. Therefore, crystallization of thalidomide from methanol solution occurs 
just before complete evaporation of the solution. In addition, methanol has relatively 
low boiling point. Because of these properties, optimizing evaporation ratio of 
methanol solution for crystallization is difficult. In some cases, colored crystals, whose 
color is thought to arise from impurities, were obtained by completely evaporating the 
solution. Thus, preliminary experiments of crystallization from methanol solution with 
solvent evaporation technique failed to obtain crystals with proper size and quality. 
In the case of crystallization from methanol solution, spending a long time on will 
be undesirable because racemization of thalidomide progress in methanol solution. 
Considering this point, preliminary experiments attempted to crystallize from methanol 
solution with solvent evaporation technique. this attempt because optimizing 
crystallization conditions is difficult due to poor solubility and low boiling point.  
While water is easier to control evaporation ratio than methanol because of higher 
boiling point than methanol, methanol has advantage in solubility of thalidomide 
compared to water. Considering these points and the property of methanol being 
miscible with water, crystallization from mixed solution of methanol and water with 
solvent evaporation technique were attempted. In this case, complete evaporation of 
the solution should be easily avoided. To increase solubility of thalidomide in the 
mixed solvent, the ratio of methanol prefers to be as high as possible. As a result of 
observation for evaporation ratio with gradually changing the mixing ratio, the optimal 
ratio was determined as methanol:water = 5:3. Thus, methanol-water (5:3) was selected 
as a polar solvent for crystallization of thalidomide. 
However, crystallizations of enantiomeric thalidomide from polar solutions require 
special attention because an undesirable reaction of racemization progress in polar 
protic solvents such as water and methanol. In crystallization of enantiomeric 
thalidomide, the enantiomeric isomers generated through racemization are nothing but 
impurities. Nevertheless, single crystals of enantiomeric thalidomide may be 
obtainable by crystallizing before the racemization has completely proceeded. The 
racemization mechanism of thalidomide is proposed as chiral inversion via 
base-catalyzed keto-enol tautomerism (Figure 2.1) [12]. According to this mechanism, 
the racemization of thalidomide will be avoidable in polar aprotic and nonpolar 
solvents. 
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Chloroform is one of common nonpolar solvents. According to the proposed 
mechanism, the chloroform solution of thalidomide should be suitably free from 
problem of racemization. In addition, (R)-thalidomide molecules in chloroform 
solution are indicated to exist in dynamic equilibrium of three isomeric dimers which 
differ in the hydrogen bonded ring moieties (Figure 2.2) [13]. With this indication, 
behavior of thalidomide molecules at cluster formation in nonpolar chloroform 
solution is expected to fundamentally different from that in polar methanol-water 
solution. Therefore, this study selected chloroform as a nonpolar solvent for 
crystallization. 
In the case of crystallization from methanol-water solution, solubility of 
thalidomide in methanol-water is relatively poor. To increase the solubility, moderate 
heating is desired. Furthermore, spending long time will be unfavorable due to 
racemization. To appropriately increase the solubility and accelerate the evaporation of 
solvent, crystallization with solvent evaporation technique from methanol-water 
solution was attempted at temperatures around 50 °C. 
In the case of crystallization from chloroform solution, chloroform has relatively 
high solubility of thalidomide at room temperature. Preliminary experiments 
demonstrate the solubilities of enantiomeric and racemic thalidomides in chloroform at 
room temperature are about 28.7 mM and 5.5 mM, respectively. These solubilities 
Figure 2.1 Chiral inversion via base-catalyzed keto-enol tautomerism. 
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appeared to be enough to attempt crystallization with vapor diffusion technique. The 
vapor diffusion technique requires the poor solvent of thalidomide with low boiling 
point and being miscible in chloroform. Diethyl ether is one of common nonpolar 
solvents and satisfies above requirements. Therefore, this study evaporated the 
chloroform solution at room temperature. Moreover, as a further experiment, 
crystallization with vapor diffusion technique, diffusing diethyl ether into chloroform 
solutions, was also attempted at room temperature. 
On the basis of above consideration, this study attempted following three methods 
for crystallization of (S)- and (RS)-thalidomides: 
･ solvent evaporation technique from methanol-water solution; 
･ solvent evaporation technique from chloroform solution; 
･ vapor diffusion technique from chloroform solution. 
 
 
 
 
 
 
 
  
Figure 2.2 Dynamic equilibrium of three isomeric (R)-thalidomide dimers in chloroform 
solution [13]. Color code: C: gray, N: blue, O: red, H: white. 
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2.3 Estimation of chiral inversion with CD spectrometry 
 
Although chiral inversion of thalidomide is unavoidable in methanol-water solution, 
single crystals of enantiomeric thalidomide are thought to be obtainable by 
crystallizing before the racemization has completely proceeded. While chiral HPLC is 
generally used for quantitative estimation of chiral inversion, CD measurement has 
advantage in minute observation of time course. Therefore, chiral inversions of 
(S)-thalidomide in crystallization conditions were estimated with CD measurements. 
 
 
2.3.1 Basic theory of circular dichroism measurement 
 
CD is an optical property that a substance shows different absorbance for left circularly 
polarized (LCP) and right circularly polarized (RCP) lights. Linearly polarized light is 
identified as a sum of LCP and RCP lights in the same amplitude. Therefore, CD turns 
the incident linearly polarized light into the elliptically polarized light with passing 
through the substance. The difference between absorbencies for LCP and RCP lights is 
expressed as 
,rl AAA   (2.1)  
where Al and Ar represent the absorbance of LCP and RCP lights, respectively. Applying 
Beer–Lambert law into this equation leads the following equation: 
  ,CLA rl    (2.2)  
where εl and εr represent molar absorptivity for LCP and RCP lights, respectively. C is 
the molar concentration and L is the length of light path. The molar circular dichroism Δε 
is defined as 
,rl    (2.3)  
and then the molar ellipticity [θ] is expressed as 
  .180
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Generally, this molar ellipticity is measured as the intensity of CD. 
CD essentially originates from chirality of substances. Thus the CD experiments 
are widely applied to a number of researches on chiral substances. CD of one 
enantiomer has same amplitude and reverse sign of the other. Therefore, racemate, a 
mixture of enantiomers in equal amount, does not exhibit CD.  
 
 
2.3.2 Materials 
 
(S)-thalidomide was purchased from Sigma-Aldrich, Inc. Methanol, chloroform, diethyl 
ether, and acetonitrile were purchased from Wako Pure Chemical Industries, Ltd. 
 
 
2.3.3 Experimental method 
 
Measurement conditions were determined based on the crystallization conditions. To 
estimate the chiral inversion ratio in protic methanol-water solution, time course in CD 
spectra of 0.2 mM methanol-water solutions of (S)-thalidomide was measured at 50 °C 
for 10 hours. The mixture ratio of methanol-water is the same 5:3 as that of mixed 
solvent for crystallization. In addition, to confirm stability to chiral inversion in aprotic 
and nonpolar solutions, chloroform, diethyl ether, and acetonitrile solutions of 
(S)-thalidomide were conducted. Time course in CD spectra of 0.1 mM chloroform, 0.1 
mM diethyl ether, and 0.1 mM acetonitrile solutions of (S)-thalidomides were measured 
at room temperature for 48 hours. 
These measurements were immediately started after preparation of the solutions. 
However, chiral inversion during dissolution was not exactly considered in this 
estimation. Thus, it should be noted that these estimations are somewhat less 
quantitative in this point. 
All CD measurement was conducted using JASCO J-820 spectrometer. A 
rectangular quartz cell of 10 mm light-path length was used. The measurement 
conditions were as follows: step scan measurement, 1 nm bandwidth, 2 sec response 
time, standard sensitivity, 1 nm wavelength resolution. 
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2.3.4 Result for protic methanol-water solution 
 
CD spectra of 0.2 mM (S)-thalidomide methanol-water solution measured every 1 h at 
50 °C are shown in Figure 2.3. The CD peak around 250 nm is obviously observable 
after 10 hours. This result supports that procession of racemization will be incomplete in 
10 hours, although chiral inversion during dissolution was not exactly considered in this 
estimation as mentioned above. Therefore, single crystals of enantiomeric thalidomide 
will be obtainable from protic methanol-water solution by crystallizing in a few hours. 
 
 
 
 
 
 
  
Figure 2.3 CD spectra of (S)-thalidomide methanol-water solution measured every 1 hour. 
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2.3.5 Result for polar aprotic and nonpolar solutions  
 
To confirm stability to chiral inversion in polar aprotic and nonpolar solutions, CD 
spectra of 0.1 mM chloroform, diethyl ether, and acetonitrile solutions were measured at 
room temperature (Figure 2.4-2.6). In the results of chloroform and acetonitrile solutions, 
the CD peaks around 250 nm remain almost unchanged for 48 hours. Although the result 
of diethyl ether solution shows slight increase of the peak intensity, this should be caused 
by rise of the concentration due to high volatility of diethyl ether. Therefore, it is 
confirmed that chiral inversion of thalidomide is surely avoidable in polar aprotic and 
nonpolar solutions. 
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Figure 2.4 CD spectra of (S)-thalidomide chloroform solution measured every 12 hour. 
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Figure 2.5 CD spectra of (S)-thalidomide diethyl ether solution measured every 24 hour. 
Figure 2.6 CD spectra of (S)-thalidomide acetonitrile solution measured every 12 hour. 
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2.4 Crystallization of (S)- and (RS)-thalidomides 
 
2.4.1 Materials 
 
(S)- and (RS)-thalidomides were purchased from Sigma-Aldrich, Inc. Methanol, 
chloroform, diethyl ether, and acetonitrile were purchased from Wako Pure Chemical 
Industries, Ltd. 
 
 
2.4.2 Solvent evaporation technique from methanol-water solution 
 
To avoid excess chiral inversion, (S)-thalidomide was crystallized in about 4 hours 
based on the result of CD measurement. In addition, to compare with the case of 
(S)-thalidomide, (RS)-thalidomide was also crystallized in about 4 hours. 
Crystallization procedure of (S)-thalidomide with solvent evaporation technique 
from methanol-water solution was as follows: 
(1) (S)-thalidomide powder (50 mg) was dissolved in 40 ml methanol-water (5:3). 
(2) The solution was evaporated for about 4 h at 50 °C. 
(3) The grown crystals floating on the solutions were filtered out. 
Crystallization procedure of (RS)-thalidomide with solvent evaporation technique from 
methanol-water solution was as follows: 
(1) (RS)-thalidomide powder (50 mg) was dissolved in 40 ml methanol-water (5:3). 
(2) The solution was evaporated for about 4 h at 50 °C. 
(3) The grown crystals floating on the solutions were filtered out. 
 
 
2.4.3 Solvent evaporation technique from chloroform solution 
 
Crystallization procedure of (S)-thalidomide with solvent evaporation technique from 
chloroform solution was as follows: 
(1) (S)-thalidomide powder (77.3 mg) was dissolved in 14 ml chloroform. 
(2) The solution was evaporated in a few days at room temperature. 
(3) The grown crystals floating on the solutions were filtered out. 
Crystallization procedure of (RS)-thalidomide with solvent evaporation technique from 
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chloroform solution was as follows: 
(1) (RS)-thalidomide powder (6.28 mg) was dissolved in 4.8 ml chloroform. 
(2) The solution was evaporated in a few days at room temperature. 
(3) The grown crystals floating on the solutions were filtered out. 
 
 
2.4.4 Vapor diffusion technique from chloroform solution 
 
Crystallization procedure of (S)-thalidomide with vapor diffusion technique from 
chloroform solution was as follows: 
(1) (S)-thalidomide powder (7.0 mg) was dissolved in 1 ml chloroform. 
(2) The inner vial containing 1 ml of this chloroform solution was put in the outer 
beaker with about 20 ml of diethyl ether. 
(3) This outer beaker was kept sealed for a few days at room temperature. 
(4) The grown crystals were filtered out. 
Crystallization procedure of (RS)-thalidomide with vapor diffusion technique from 
chloroform solution was as follows: 
(1) (RS)-thalidomide powder (64.5 mg) was dissolved in 50 ml chloroform. 
(2) The inner vial containing 50 ml of this chloroform solution was put in the outer 
beaker with about 80 ml of diethyl ether. 
(3) This outer beaker was kept sealed for a few days at room temperature. 
(4) The grown crystals were filtered out. 
 
 
2.5 Polarizing microscope observation and thermal analysis  
 
2.5.1 Experimental method 
 
Habits of all crystals were observed with polarizing microscope. Furthermore, 
possibilities of polymorphs or solvates were investigated with TG-DTA. TG-DTA was 
conducted without grinding each crystal using Rigaku TG8120 with heating rate of 
10.0 °C min
-1
. 
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2.5.2 Crystals obtained with solvent evaporation technique from 
 methanol-water solution 
 
From the solution of (S)-thalidomide, needle shaped crystals (I) were obtained (Figure 
2.7(A)). Similarly, from the solution of (RS)-thalidomide, needle shaped crystals (II) 
were obtained (Figure 2.7(B)). These results suggest that visually identifying the 
crystals of (RS)-thalidomide, which are generated by racemization of (S)-thalidomide, in 
the crystals obtained from solution of (S)-thalidomide will be impossible because the 
similar needle shaped crystals were obtained from solution of (RS)-thalidomide. 
TG-DTA on 4.7 mg of I shows endothermic peaks around 240 °C and 270 °C 
(Figure 2.8(A)). The melting points of enantiomeric and racemic thalidomides are 
reported to be 241 °C and 271 °C, respectively [14]. According to this report, those 
two endothermic peaks indicates that I is mixture of (S)- and (RS)-thalidomides. 
TG-DTA on I also shows exothermic peak around 250 °C. This exothermic peak 
indicates possibility of polymorphic transformation of (S)-thalidomide because the 
weight is not increased. On the other hand, TG-DTA on 2.6 mg of II shows 
endothermic peaks around 270 °C (Figure 2.8(B)). This peak is reasonable because of 
consistency with known melting point of (RS)-thalidomide. TG-DTA on each of I and 
II shows the no weight reduction arising from solvent desorption. Therefore, both I 
and II are thought to be unsolvates. 
 
   
Figure 2.7 Polarizing microscopic images of needle shaped crystals of (A) (S)- and (B) 
(RS)-thalidomides crystallized with solvent evaporation technique from methanol water 
solutions. The scale bars represent 0.5 mm. 
(A) (B) 
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2.5.3 Crystals obtained with solvent evaporation technique from chloroform 
 solution 
 
From the solution of (S)-thalidomide, rod shaped crystals (III) were obtained (Figure 
9(A)). Whereas, from the solution of (RS)-thalidomide, plate shaped crystals (IV) were 
obtained (Figure 9(B)). Comparing with the results of crystallization from 
methanol-water solution, crystal habits of both III and IV are different from those of I 
and II. This result suggests that those crystals are possibly polymorphs or solvates. 
TG-DTA on 5.9 mg of III shows endothermic peak with weight reduction around 
125 °C (Figure 2.10(A)). Therefore, III is thought to be solvates. In addition, no peaks 
around 270 °C support that racemization of thalidomide is not proceed in chloroform 
solution. TG-DTA on 2.2 mg of IV shows endothermic peaks around 270 °C (Figure 
2.10(B)). This result on IV is almost similar to that on II. Therefore, IV may be 
isomorphic unsolvate with II, although those habits are significantly different. 
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Figure 2.8 TG-DTA curves of (A) (S)-thalidomide crystals (I) and (B) (RS)-thalidomide 
crystals (II). 
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Figure 2.9 Polarizing microscopic images of (A) rod shaped crystals of (S)-thalidomide and 
(B) plate shaped crystals of (RS)-thalidomide crystallized with solvent evaporation technique 
from chloroform solutions. The scale bars represent 0.5 mm. 
(A) (B) 
Figure 2.10 TG-DTA curves of (A) (S)-thalidomide crystals (III) and (B) (RS)-thalidomide 
crystals (IV). 
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2.5.4 Crystals obtained with vapor diffusion technique from chloroform 
 solution 
 
From the solution of (S)-thalidomide, rod shaped (V) and plate shaped (VI) crystals 
were concomitantly obtained (Figure 2.11(A)). These rod shaped crystals were almost 
similar to III. From the solution of (RS)-thalidomide, only plate shaped crystals (VII) 
were obtained (Figure 2.11(B)). These plate shaped crystals were almost similar to the 
plate shaped VI. 
TG-DTA of V and VI were conducted on visually identified crystals from the 
mixture based on those different habits. Therefore, each of result may be negatively 
affected by the other. TG-DTA on 1.1 mg of V shows slightly noisy peaks because the 
amount of analyzed crystal was relatively small (Figure 2.12(A)). Similarly to III, the 
endothermic peak with weight reduction around 150 °C indicates that V is solvate. 
TG-DTA on 3.8 mg of VI shows marginal endothermic peaks with great weight 
reduction around 150 °C (Figure 2.12(B)). This weight reduction is too great to regard 
the cause as desorption of included solvent. Therefore, judging whether VI is solvate 
or unsolvate from this result is difficult. TG-DTA of VII was not conducted because 
the total amount of obtained crystals was not enough to appropriately conduct 
TG-DTA. 
 
   
 
Figure 2.11 Polarizing microscopic images of (A) rod and plate shaped crystals of 
(S)-thalidomide and (B) plate shaped crystal of (RS)-thalidomide crystallized with vapor 
diffusion technique from chloroform solutions. The scale bars represent 0.5 mm. 
(A) (B) 
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Figure 2.12 TG-DTA curves of (A) rod shaped (S)-thalidomide crystals (V) and (B) plate 
shaped (S)-thalidomide crystals (VI). 
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2.6 Conclusion 
 
In this chapter, this study evaluates methods for crystallization of thalidomide. 
Considering possibilities of multiple forms, i.e. polymorphs or solvates, three different 
methods were determined in terms of selection of solvent and technique for 
crystallization. Undesirable chiral inversion in protic methanol-water solution and 
stability to chiral inversion in aprotic and nonpolar solutions were estimated with CD 
spectrometry. As summarized in Table 2.1, crystallizations with three different methods 
produced crystals with different habits. These results suggest that visually identifying 
the crystals of (RS)-thalidomide, which are generated by racemization of 
(S)-thalidomide, in the crystals obtained from solution of (S)-thalidomide will be 
impossible because the similar needle shaped crystals were obtained from solutions of 
both (S)- and (RS)-thalidomide. The results of TG-DTA suggested that I, II, and IV 
should be unsolvate and III and V should be solvate. On the basis of these results, all 
crystal structures of (S)- and (RS)-thalidomides are investigated in chapter 3 and 4, 
respectively. 
As future works, possibility of polymorphic transformation of (S)-thalidomide, 
which is indicated by exothermic peak without weight increase around 250 °C in 
TG-DTA on I, and the cause of the excess weight reduction around 150 °C in TG-DTA 
on VI, should be investigated. 
 
 
Table 2.1 Comparison of crystal habits between (S)- and (RS)-thalidomide crystals obtained 
with three different methods. 
Solvent Technique 
Solute 
(S)-thalidomide (RS)-thalidomide 
methanol-water solvent evaporation needle (I) needle (II) 
chloroform solvent evaporation rod (III) plate (IV) 
chloroform-diethyl ether vapor diffusion rod (V) / plate (VI) plate (VII) 
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3. Determination of crystal structure and 
absolute configuration of (S)-thalidomide 
 
 
 
3.1 Introduction 
 
Crystal structures are fundamental knowledge of substances. Determinations of crystal 
structures provide detail information of component molecules, such as those 
conformations and relative position to another molecule. Physicochemical properties 
such as solubility and melting point are directly related with the structural stability of the 
crystal. In the case of chiral compounds, crystal structures of enantiomeric and racemic 
compounds are essentially different: enantiomeric crystals consist of either enantiomer, 
and racemic crystals consist of both enantiomeric isomers. Therefore, knowledge about 
structures of not only racemic crystal but also the enantiomeric crystal is significant for 
understanding the physicochemical properties of chiral compounds. Crystal structures 
of racemic thalidomide have been investigated since 1971 [1]. However, crystal 
structures of enantiomeric thalidomide have not been reported. 
To determine crystal structure and absolute configuration of enantiomeric 
thalidomide, this study attempted to crystallize (S)-thalidomide. Considering chiral 
inversion of (S)-thalidomide and possibility for multiple forms, three different 
crystallization methods were attempted. All crystal structures were investigated with 
single crystal X-ray diffractometry. 
 
 
3.2 Crystallization of (S)-thalidomide 
 
3.2.1 Materials 
 
(S)-thalidomides was purchased from Sigma-Aldrich, Inc. Methanol, chloroform, 
diethyl ether, and acetonitrile were purchased from Wako Pure Chemical Industries, 
Ltd. 
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3.2.2 Experimental method 
 
On the basis of the evaluation in chapter 2, (S)-thalidomide crystals were obtained with 
following three different crystallization methods: 
･ solvent evaporation technique from methanol-water solution; 
･ solvent evaporation technique from chloroform solution; 
･ vapor diffusion technique from chloroform solution. 
Detail procedures of crystallization are as follows. 
Crystallization procedure of (S)-thalidomide with solvent evaporation technique 
from methanol-water solution was as follows: 
(1) (S)-thalidomide powder (50 mg) was dissolved in 40 ml methanol-water (5:3). 
(2) The solution was evaporated for about 4 h at 50 °C. 
(3) The grown crystals floating on the solutions were filtered out. 
Crystallization procedure of (S)-thalidomide with solvent evaporation technique from 
chloroform solution was as follows: 
(1) (S)-thalidomide powder (77.3 mg) was dissolved in 14 ml chloroform. 
(2) The solution was evaporated in a few days at room temperature. 
(3) The grown crystals floating on the solutions were filtered out. 
Crystallization procedure of (S)-thalidomide with vapor diffusion technique from 
chloroform solution was as follows: 
(1) (S)-thalidomide powder (7.0 mg) was dissolved in 1 ml chloroform. 
(2) The inner vial containing 1 ml of this chloroform solution was put in the outer 
beaker with about 20 ml of diethyl ether. 
(3) This outer beaker was kept sealed for a few days at room temperature. 
(4) The grown crystals were filtered out. 
 
 
3.2.3 Results 
 
Crystallization with solvent evaporation technique from methanol-water solution of 
(S)-thalidomide produced needle shaped crystals (I) (Figure 3.1(A)). To avoid excess 
chiral inversion, (S)-thalidomide was crystallized in about 4 hours at temperatures 
around 50 °C. In this case, (RS)-thalidomide crystals arising from the chiral inversion 
of (S)-thalidomide should be mixed with the crystals of (S)-thalidomide. However, 
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visually identifying the crystals of (RS)-thalidomide is impossible due to those almost 
same shapes. Therefore, (S)-thalidomide crystals were identified with repeated trials. 
Crystallization with solvent evaporation technique from chloroform solution of 
(S)-thalidomide produced rod shaped crystals (III) (Figure 3.1(B)).Crystallization with 
vapor diffusion technique from chloroform solution of (S)-thalidomide concomitantly 
produced rod shaped (V) and plate shaped (VI) crystals (Figure 3.1(C)). As 
demonstrated in chapter 2, chloroform and diethyl ether solutions of enantiomeric 
thalidomide are free from chiral inversion. Therefore, crystals obtained from 
chloroform solutions were regarded without special attention to the chiral inversion. 
 
 
 
   
 
(A) (B) 
(C) 
Figure 3.1 Polarizing microscopic images of (S)-thalidomide crystals obtained with (A) solvent 
evaporation technique from methanol-water solution (B) solvent evaporation technique from 
chloroform solution (C) vapor diffusion technique from chloroform solution. The scale bars 
represent 0.5 mm. 
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3.3 X-ray diffractometry on (S)-thalidomide crystals 
 
3.3.1 Experimental method 
 
Some points should be paid attention in selection of crystals for X-ray diffractometry. 
To minimize directional dependency in measurement, shape of the crystal is preferably 
similar to sphere. The least cracks on the crystal are desired due to its negative 
influence on diffraction. Moreover, particularly for film shaped crystal, possible 
existence of twined crystals, which appeared an isolated single crystal but is actually 
piled units of some single crystals with slight misalignments, should be cared. In this 
case, carefully observing extinction of transmitted light from crystal using polarizing 
microscope is important. Considering these points, crystals for X-ray diffractometry 
were selected. 
X-ray diffraction data for all crystals (I, III, V, and VI) were collected using a 
Rigaku RAXIS RAPID imaging plate detector with graphite monochromated Cu-Kα 
radiation. Crystal structures were solved by direct methods and refined by full-matrix 
least-squares on F
2 
[2]. Non-hydrogen atoms were refined with anisotropic 
displacement parameters, except for isotropically refined solvent molecules. Hydrogen 
atoms were refined using the riding model. Absolute configurations were determined 
based on Flack parameters. 
 
 
3.3.2 Summary of results 
 
As a result of single crystal X-ray diffractometry, I and VI are revealed to be unsolvate 
of (S)-thalidomide. VI is determined as the isomorphic form with I. On the other hand, 
III and V are revealed to be solvate of (S)-thalidomide. Crystal and structure 
refinement data are summarized in Table 3.1. Detail crystal structures of unsolvated 
and solvated (S)-thalidomide are discussed in Section 3.3.3 and Section 3.3.4, 
respectively. 
Rint is the degree of agreement on equivalent reflections. R1 and wR2 are the 
unweighted and weighted degrees of agreement on structure factors based on 
calculated and observed reflections, respectively. Max Shift/Error is the indicator of 
convergence in the structure refinement, and is favorable to be almost equal to 0. 
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Goodness of fit represents the suitability of weighting, and is favorable to be almost 
equal to 1. Flack parameter is the indicator of absolute configuration. This parameter 
being almost equal to 0 means the absolute configuration is true. 
To crystallographically determine the crystal structure, the result of single crystal 
X-ray diffractometry needs to fulfill the following requirements: 
 Rint < 0.1 
 R1 ≦ 0.1 
 wR2 < 0.25 
 -0.01 < Max Shift/Error < 0.01 
 0.8 ≦ Goodness of fit ≦ 2.0 
According to these requirements, the crystal structure of III is crystallographically 
undetermined. Nevertheless, III is concluded to be chloroform solvate of 
(S)-thalidomide based on result of TG-DTA and comparison with V as described in 
section 3.3.3. 
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Table 3.1 Crystal and structure refinement data. The data for III is the final result of 
incomplete refinement, and the ratio of chloroform is assumed. 
 I III  V VI 
Empirical formula C13H10O4N2 C13.25H10.25N2O4Cl0.75 C14.25H12.75Cl0.75N2O4.25 C13H10O4N2 
M (g mol-1) 258.23 288.08 306.61 258.23 
Temperature (K) 93(1) 223(1) 153(1) 263(1) 
Crystal system monoclinic orthorhombic orthorhombic monoclinic 
Space group P21 P21212 P21212 P21 
a (Å) 8.40187 (15) 13.4826(2) 13.2889(2) 8.3513(4) 
b (Å) 10.02372 (18) 31.1367(5) 30.502(2) 10.1578(5) 
c (Å) 14.4814 (7) 7.05915(10) 7.05698(10) 14.7613(7) 
β (°) 103.4938 (8) - - 103.590(3) 
V (Å3) 1185.93 (7) 2963.46(8) 2860.5(2) 1217.16(10) 
Z 4 8 8 4 
D (g cm-3) 1.446 1.291 1.424 1.409 
Reflection total/unique 13965/3822 32785/5331 33446/5162 12696/4236 
Rint 0.025 0.136 0.033 0.063 
R1 [I > 2σ(I)] 0.0328 0.1223 0.0748 0.0392 
wR2 (all data) 0.0844 0.3558 0.2243 0.1084 
Max Shift/Error 0.000 0.202 0.000 0.004 
Goodness of fit 1.094 1.553 1.051 0.938 
Flack Parameter 0.05(18) 0.10(11) 0.09(6) 0.0(2) 
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3.3.3 Crystal structures of unsolvated (S)-thalidomide 
 
Both I and VI are revealed to be unsolvate of (S)-thalidomide. Although VI is 
determined as the isomorphic form with I, the result of structural refinement on I is 
better than that on VI. Therefore, this study focuses on I as the crystal structure of 
unsolvated (S)-thalidomide. 
The crystal structure of unsolvated (S)-thalidomide is revealed to be formed with 
two conformational isomers, i.e. two (S)-thalidomide molecules with different 
conformation. To distinguish these two conformational isomers, they are hereafter 
designated as S1 and S2, respectively. The unit-cell structure is shown in Figure 3.2. 
The packing structures are shown in Figure 3.3. 
 
  
Figure 3.2 The unit-cell structure of (S)-thalidomide crystal drawn with thermal ellipsoids at 
50% probability level. Brown axes represent 2-fold screw axes. Color code: C: gray, N: blue, O: 
red, H: white. 
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(A) (B) 
(C) 
Figure 3.3 Packing structures of unsolvated (S)-thalidomide crystal drawn with thermal 
ellipsoids at 50% probability level: (A) along a axis, (B) along b axis, (C) along c axis. S1 and 
S2 are colored by symmetry equivalence as green and blue, respectively. 
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A thalidomide molecule consists of phthalimide ring (C1-C8, N1, O1, O2) and 
glutarimide ring (C9-C13, N2, O3, O4). The differences in corresponding bond length 
between S1 and S2 are tested with the following t value: 
   2
22 LL
LL
SS1
S2S1
 

t
 
(3.1)  
where 
2t  
 
: the difference is not significant,  
522 .t  : the difference is probably significant,  
t5.2  
 
: the difference is significant.  
Here S1L and 2LS  represent the length of particular bond in S1 and S2, respectively. In 
addition, the differences in corresponding bond angle between S1 and S2 are 
analogically evaluated of the based above test. The all bond lengths are listed in Table 
3.2. The bond angles of phthalimide and glutarimide rings are listed in Table 3.3 and 
Table 3.4, respectively. 
As indicated in Figure 3.4, significant differences in corresponding bond length 
between S1 and S2 limitedly exist at N1-C8 and C6-C7 bonds in the phthalimide ring, 
and N2-C10 and C9-C13 bonds in the glutarimide ring. The differences in each of the 
corresponding bond lengths between S1 and S2 are 0.011(4) Å for N1-C8, 0.013(4) Å 
for C6-C7, 0.011(3) Å for N2-C10, and 0.010(4) Å for C9-C13, respectively, where 
values in the parentheses represent standard deviations. Such crystal structure formed 
with two conformational isomers is not unique for (S)-thalidomide but also shown in 
other compounds (e.g. L-leucine [3], L-valine [4, 5], L-cysteine [6]). 
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Table 3.2 The list of bond lengths in S1 and S2. The values in the parentheses represent standard 
deviations. The t values over 2 are colored in orange. 
Bond LS1 / Å LS2 / Å |LS1-LS2| / Å t 
O1-C1 1.205(2) 1.205(2) 0.000(3) 0.00  
O2-C8 1.218(3) 1.214(2) 0.004(4) 1.11  
N1-C1 1.413(3) 1.409(2) 0.004(4) 1.11  
N1-C8 1.400(2) 1.411(3) 0.011(4) 3.05  
C1-C2 1.492(2) 1.494(2) 0.002(3) 0.71  
C2-C3 1.379(3) 1.371(3) 0.008(4) 1.89  
C2-C7 1.385(3) 1.386(3) 0.001(4) 0.24  
C3-C4 1.392(3) 1.398(3) 0.006(4) 1.41  
C4-C5 1.395(3) 1.393(3) 0.002(4) 0.47  
C5-C6 1.393(3) 1.393(3) 0.000(4) 0.00  
C6-C7 1.380(3) 1.393(3) 0.013(4) 3.06  
C7-C8 1.480(3) 1.482(2) 0.002(4) 0.55  
     N1-C9 1.453(2) 1.450(2) 0.003(3) 1.06  
     O3-C10 1.210(2) 1.213(2) 0.003(3) 1.06  
O4-C11 1.223(2) 1.223(2) 0.000(3) 0.00  
N2-C10 1.379(2) 1.390(2) 0.011(3) 3.89  
N2-C11 1.382(3) 1.377(2) 0.005(4) 1.39  
C9-C10 1.521(3) 1.514(3) 0.007(4) 1.65  
C9-C13 1.518(3) 1.528(3) 0.010(4) 2.36  
C11-C12 1.501(3) 1.502(3) 0.001(4) 0.24  
C12-C13 1.524(3) 1.522(2) 0.002(4) 0.55  
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Table 3.3 The list of bond angles of phthalimide rings in S1 and S2. AS1 and AS2
 
represent the 
angle of particular bond in S1 and S2, respectively. The values in the parentheses represent 
standard deviations. The t values over 2 are colored in orange. 
Bond AS1 / deg AS2 / deg |AS1-AS2| / deg t 
C1-N1-C8 111.26(17) 111.66(16) 0.40(23) 1.71  
C1-N1-C9 125.14(18)  123.98(18) 1.16(25) 4.56  
C8-N1-C9 121.0(2) 122.09(18)  1.09(27) 4.05  
O1-C1-N1 125.2(2) 124.17(18) 1.03(27) 3.83  
O1-C1-C2 129.5(2)  130.2(2)  0.7(3) 2.47  
N1-C1-C2 105.35(19) 105.64(19) 0.29(27) 1.08  
C1-C2-C3 130.0(2)  130.7(2)  0.7(3) 2.47  
C1-C2-C7 108.2(2) 107.77(18) 0.43(27) 1.60  
C3-C2-C7 121.82(19)  121.5(2)  0.32(28) 1.16  
C2-C3-C4 116.7(2) 117.4(2) 0.7(3) 2.47  
C3-C4-C5 121.7(2)  121.4(2)  0.3(3) 1.06  
C4-C5-C6 120.8(2) 120.9(2) 0.1(3) 0.35  
C5-C6-C7 117.1(2)  116.9(2)  0.2(3) 0.71  
C2-C7-C6 121.8(2) 121.9(2) 0.1(3) 0.35  
C2-C7-C8 108.55(18)  109.33(19)  0.78(26) 2.98  
C6-C7-C8 129.6(2) 128.8(2) 0.8(3) 2.83  
O2-C8-N1 124.13(19)  105.20(19)  0.41(26) 1.57  
O2-C8-C7 129.8(2) 130.3(2) 0.5(3) 1.77  
N1-C8-C7 106.0(2)  124.54(18)  0.8(28) 2.90  
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Table 3.4 The list of bond angles of glutarimide rings in S1 and S2. AS1 and AS2 represent the 
angle of particular bond in S1 and S2, respectively. The values in the parentheses represent 
standard deviations. The t values over 2 are colored in orange. 
Bond AS1 / deg AS2 / deg |AS1-AS2| / deg t 
N1-C9-C10 109.57(19) 108.92(18)  0.65(26) 2.48  
N1-C9-C13 115.0(2) 114.35(18) 0.65(27) 2.42  
C10-C9-C13 111.46(18) 111.00(19)  0.46(26) 1.76  
O3-C10-N2 121.8(2) 120.5(2) 1.3(3) 4.60  
O3-C10-C9 122.80(18) 124.15(18)  1.35(25) 5.30  
N2-C10-C9 115.30(19)  115.32(19) 0.02(27) 0.07  
C10-N2-C11 127.2(2)  126.59(19)  0.61(28) 2.21  
O4-C11-N2 119.5(2) 119.6(2)  0.1(3) 0.35  
O4-C11-C12 123.3(2)  122.7(2) 0.6(3) 2.12  
N2-C11-C12 117.22(18) 117.65(17)  0.43(25) 1.74  
C11-C12-C13 113.9(2)  113.9(2) 0.0(3) 0.00  
C9-C13-C12 108.9(2) 108.52(19)  0.38(28) 1.38  
 
 
 
 
 
  
Figure 3.4 The conformation of S1 drawn with thermal ellipsoids at 50% probability level. 
Bonds, of which lengths are significantly different between S1 and S2, are represented in 
orange. Color code: C: gray, N: blue, O: red, H: white. 
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Furthermore, dimer formation by pairs of S1 and S2 molecules with 
hydrogen-bonded rings at each of the glutarimide rings is also revealed (Figure 3.5). 
Generally, hydrogen bond forming between atoms of X and A as X－H…A is judged 
by the distance between X and A is less than the sum of those Van der Waals radii. The 
strength of hydrogen bond is classified as Table 3.5. Nevertheless, the 
hydrogen-bonded ring in dimers formed by pairs of S1 and S2 molecules is unable to 
directly apply to this classification due to the hydrogen-bonded ring consisting of two 
hydrogen bonds. As shown in Figure 3.6, S1 and S2 form the dimers with each of the 
corresponding S2 and S1 in the adjacent unit cell. The lengths of these two 
intermolecular hydrogen-bonds are not significantly different: 2.912(3) Å for N2-O4‟ 
and 2.910(3) Å for O4-N2‟, respectively (the primed numbers represent atoms of S2). 
Similar hydrogen-bonded rings are often formed with such as amide units with dual 
capacity of donor and acceptor. A number of reports investigated in detail or 
systematically analyzed those hydrogen-bonded rings [7, 8]. 
 
 
Figure 3.5 The dimer formation in (S)-thalidomide crystal drawn with thermal ellipsoids at 50% 
probability level. Green broken lines represent hydrogen bonds. Color code: C: gray, N: blue, O: 
red, H: white. 
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Strong Moderate Weak 
interaction type 
strongly 
covalent 
mostly 
electrostatic 
electrostatic / 
dispersion 
H…A [Å] 1.2-1.5 1.5-2.2 >2.2 
X－A [Å] 2.2-2.5 2.5-3.2 >3.2 
X－H versus H…A X－H≒H…A X－H < H…A X－H << H…A 
lengthening of X－H [Å] 0.08-0.25 0.02-0.08 <0.02 
directionality strong moderate weak 
bond angles [deg] 170-180 >130 >90 
 
 
 
 
 
 
 
  
Table 3.5 The classification of strong, moderate, and weak hydrogen bonds. 
Figure 3.6 The packing structure and dimer formations by hydrogen-bonded rings. 
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In addition, (R)-thalidomide molecules in chloroform solution are suggested to 
exist in dynamic equilibrium of three isomeric dimers which differ in the hydrogen 
bonded ring moieties (Figure 3.7) [9]. Moreover, density functional theory calculation 
demonstrated that the most populated dimer is the lowest energy one (Table 3.6). The 
two hydrogen bonding moieties of dimers in (S)-thalidomide unsolvated crystal are the 
same as those of the most populated dimer of (R)-thalidomide in chloroform solution. 
 
 
 
 
Dimer Electronic energy [kcal/mol] Population 
2-AA -1144431.463 0.235970024 
2-AB -1144431.613 0.335168207 
2-BB -1144431.674 0.428861769 
  
Figure 3.7 Dynamic equilibrium of three isomeric (R)-thalidomide dimers in chloroform solution 
[9]. Color code: C: gray, N: blue, O: red, H: white. 
Table 3.6 Calculated Electronic energies (B3LYP/6-31G*) and 
populations of each dimers [9]. 
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3.3.4 Crystal structures of solvated (S)-thalidomide 
 
As a result of single crystal X-ray diffractometry, both III and V are revealed to be 
solvate of (S)-thalidomide. 
On one hand, the rod shaped III is concluded to be chloroform solvate of 
(S)-thalidomide. Although structure refinement is incomplete due to disordered 
chloroform molecules, the clathrate structure of host lattice formed with 
(S)-thalidomide molecules is almost determined (Figure 3.8). The final result of 
incomplete refinement is shown in Table 3.7. Disordered chloroform molecules appear 
to be confined into the channel spaces. The inclusion of chloroform molecules is also 
demonstrated in TG-DTA by the weight reduction at temperatures around 125 °C 
(Figure 3.9). 
 
 
 
 
  
Figure 3.8 Packing arrangements of incompletely refined III colored by symmetry equivalence: 
(A) along c axis and (B) along a axis. Purple domains represent channel spaces where disordered 
chloroform molecules confined. 
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 III  
Empirical formula C13.25H10.25N2O4Cl0.75 
M (g mol-1) 288.08 
Temperature (K) 223(1) 
Crystal system orthorhombic 
Space group P21212 
a (Å) 13.4826(2) 
b (Å) 31.1367(5) 
c (Å) 7.05915(10) 
V (Å3) 2963.46(8) 
Z 8 
D (g cm-3) 1.291 
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Table 3.7 The crystal data for III. The values are the final result 
of incomplete refinement, and the ratio of chloroform is assumed. 
Figure 3.9 TG-DTA curves of III. 
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On the other hand, V is determined as chloroform and diethyl ether solvate of 
(S)-thalidomide. The composition ratio of V is (S)-thalidomide:chloroform:diethyl 
ether = 1:0.25:0.25. The packing arrangement of (S)-thalidomide molecules in V is 
determined as quite similar clathrate structure with III (Figure 3.10). This result 
indicates the crystallographically undetermined structure of III is almost isomorphic 
with the crystal structure of V. Disordered chloroform and diethyl ether molecules are 
confined into the channel spaces. According to the statistical study on the Cambridge 
Structural Database, each of chloroform and diethyl ether tends to form not only 
solvates but also heterosolvates, i.e. co-existing of two different solvent molecules in 
crystal. [10] Considering this tendency, the heterosolvate formation with chloroform 
and diethyl ether in V appear to be reasonable.  
 
 
 
  
Figure 3.10 Packing arrangements of V drawn with thermal ellipsoids at 50% probability level: 
(A) along c axis and (B) along a axis. Disordered chloroform and diethyl ether molecules are 
overlaid with space filling model as 100% occupancy. Color code: C: gray, N: blue, O: red, H: 
white, Cl: green. 
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The crystal data for V is shown in Table 3.8. Both this non-stoichiometric 
inclusion of solvent molecules and the similarity between clathrate structures of III 
and V imply the capability for replacing solvent molecules at channel spaces with 
maintaining the host lattice of (S)-thalidomide, as demonstrated on a drug substance of 
FK041 [11, 12]. 
The crystal structure of V is revealed to be also formed with two conformational 
isomers, similarly to the unsolvated (S)-thalidomide crystals. To distinguish these two 
conformational isomers, they are designated as S’1 and S’2, respectively. The unit-cell 
structure of V is shown in Figure 3.11. The all bond lengths are listed in Table 3.9. The 
bond angles of phthalimide and glutarimide rings are listed in Table 3.10 and Table 
3.11, respectively. Significant differences in corresponding bond length between S’1 
and S’2 exist at N1-C8 and C5-C6 bonds in the phthalimide ring, C9-C10 and C10-O3 
bonds in the glutarimide ring, and N1-C9 bond of the connector for both rings (Figure 
3.12). The differences in each of the corresponding bond lengths between S’1 and S’2 
are 0.03(7) Å for N1-C8, 0.018(8) Å for C5-C6, 0.019(7) Å for C9-C10, 0.029(7) Å for 
C10-O3, and 0.018(6) Å for N1-C9, respectively. 
 
 
 V 
Empirical formula C14.25H12.75Cl0.75N2O4.25 
M (g mol-1) 306.61 
Temperature (K) 153(1) 
Crystal system orthorhombic 
Space group P21212 
a (Å) 13.2889(2) 
b (Å) 30.502(2) 
c (Å) 7.05698(10) 
V (Å3) 2860.5(2) 
Z 8 
D (g cm-3) 1.424 
  
Table 3.8 The crystal data for V. 
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Figure 3.11 The unit-cell structure of V drawn with thermal ellipsoids at 50% probability level. 
Brown axes represent 2-fold screw axes. (A) Thalidomide molecules are colored by element as 
C: gray, N: blue, O: red, H: white. (B) S’1 and S’2 are colored by symmetry equivalence as 
green and blue, respectively. 
(A) 
(B) 
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Table 3.9 The list of bond lengths in S’1 and S’2. The values in the parentheses represent 
standard deviations. The t values over 2 are colored in orange. 
Bond LS’1 / Å LS’2 / Å |LS’1-LS’2| / Å t 
O1-C1 1.231(5) 1.219(4) 0.012(6) 1.87  
O2-C8 1.203(5) 1.213(5) 0.01(7) 1.41  
N1-C1 1.378(5) 1.385(4) 0.007(6) 1.09  
N1-C8 1.417(5) 1.387(5) 0.03(7) 4.24  
C1-C2 1.498(6) 1.493(5) 0.005(8) 0.64  
C2-C3 1.355(6) 1.366(5) 0.011(8) 1.41  
C2-C7 1.391(6) 1.401(5) 0.01(8) 1.28  
C3-C4 1.396(6) 1.383(6) 0.013(8) 1.53  
C4-C5 1.413(7) 1.400(6) 0.013(9) 1.41  
C5-C6 1.361(6) 1.379(6) 0.018(8) 2.12  
C6-C7 1.385(6) 1.379(6) 0.006(8) 0.71  
C7-C8 1.480(6) 1.484(5) 0.004(8) 0.51  
     N1-C9 1.448(5) 1.466(4) 0.018(6) 2.81  
     O3-C10 1.216(5) 1.187(5) 0.029(7) 4.10  
O4-C11 1.213(5) 1.217(5) 0.004(7) 0.57  
N2-C10 1.385(5) 1.394(5) 0.009(7) 1.27  
N2-C11 1.377(5) 1.381(5) 0.004(7) 0.57  
C9-C10 1.521(5) 1.540(5) 0.019(7) 2.69  
C9-C13 1.515(6) 1.519(5) 0.004(8) 0.51  
C11-C12 1.497(6) 1.494(5) 0.003(8) 0.38  
C12-C13 1.533(6) 1.518(5) 0.015(8) 1.92  
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Table 3.10 The list of bond angles of phthalimide rings in S’1 and S’2. AS’1 and AS’2
 
represent 
the angle of particular bond in S’1 and S’2, respectively. The values in the parentheses represent 
standard deviations. The t values over 2 are colored in orange. 
Bond AS’1 / deg AS’2 / deg |AS’1-AS’2| / deg t 
C1-N1-C8 111.26(17) 111.66(16) 0.6 1.41  
C1-N1-C9 125.14(18)  123.98(18) 1.9 4.48  
C8-N1-C9 121.0(2) 122.09(18)  1.1 2.59  
O1-C1-N1 125.2(2) 124.17(18) 0.3 0.53  
O1-C1-C2 129.5(2)  130.2(2)  1.4 2.47  
N1-C1-C2 105.35(19) 105.64(19) 1 2.36  
C1-C2-C3 130.0(2)  130.7(2)  0.8 1.41  
C1-C2-C7 108.2(2) 107.77(18) 1.6 3.77  
C3-C2-C7 121.82(19)  121.5(2)  2.4 4.80  
C2-C3-C4 116.7(2) 117.4(2) 0.9 1.59  
C3-C4-C5 121.7(2)  121.4(2)  0.8 1.41  
C4-C5-C6 120.8(2) 120.9(2) 0.5 0.88  
C5-C6-C7 117.1(2)  116.9(2)  0.3 0.60  
C2-C7-C6 121.8(2) 121.9(2) 1.6 3.20  
C2-C7-C8 108.55(18)  109.33(19)  2.4 5.66  
C6-C7-C8 129.6(2) 128.8(2) 0.7 1.40  
O2-C8-N1 124.13(19)  105.20(19)  0.5 1.00  
O2-C8-C7 129.8(2) 130.3(2) 1.8 3.60  
N1-C8-C7 106.0(2)  124.54(18)  1.2 2.83  
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Table 3.11 The list of bond angles of glutarimide rings in S’1 and S’2. AS’1 and AS’2
 
represent 
the angle of particular bond in S’1 and S’2, respectively. The values in the parentheses represent 
standard deviations. The t values over 2 are colored in orange. 
Bond AS’1 / deg AS’2 / deg |AS’1-AS’2| / deg t 
N1-C9-C10 109.57(19) 108.92(18)  1.2 2.83  
N1-C9-C13 115.0(2)  114.35(18) 0.6 1.41  
C10-C9-C13 111.46(18) 111.00(19)  0.4 0.94  
O3-C10-N2 121.8(2)  120.5(2) 0.2 0.40  
O3-C10-C9 122.80(18) 124.15(18)  0.1 0.20  
N2-C10-C9 115.30(19)  115.32(19) 0.1 0.24  
C10-N2-C11 127.2(2)  126.59(19)  0.3 0.71  
O4-C11-N2 119.5(2) 119.6(2)  0.6 1.20  
O4-C11-C12 123.3(2)  122.7(2) 0.2 0.40  
N2-C11-C12 117.22(18) 117.65(17)  0.5 1.00  
C11-C12-C13 113.9(2)  113.9(2) 2.5 5.00  
C9-C13-C12 108.9(2) 108.52(19)  1.2 2.40  
 
 
 
 
  
Figure 3.12 The conformation of S’1 drawn with thermal ellipsoids at 50% probability level. 
Bonds, of which lengths are significantly different between S’1 and S’2, are represented in 
orange. Color code: C: gray, N: blue, O: red, H: white. 
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Focusing on these conformational isomers, each of them is interacted with the 
other by hydrogen bonds. In the unsolvated crystal of (S)-thalidomide, pairs of 
conformational isomers forms dimers with the hydrogen bonded ring (Fig. 3.13(A)). 
Contrastingly, in the solvated crystal of (S)-thalidomide, alternate arrangement of 
conformational isomers forms infinite hydrogen bonded chain (Fig. 3.13(B)). 
Considering the fact that both unsolvated and solvated crystals were concomitantly 
obtained with the vapor diffusion technique, structural stabilities of each crystal appear 
to be close level. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 The structures of (A) hydrogen bonded dimer in unsolvated crystal of 
(S)-thalidomide and (B) hydrogen bonded chain in solvated crystal of (S)-thalidomide. Green 
broken lines represent hydrogen bonds. Color code: C: gray, N: blue, O: red, H: white, Cl: 
green. 
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3.4 Conclusion 
 
In this chapter, crystal structure and absolute configuration of (S)-thalidomide was 
determined with single crystal X-ray diffractometry. Despite thalidomide has been 
attracting considerable attention again because of its wide-ranging bioactivity, the 
crystal structure of the enantiomeric thalidomide had not been published for about 40 
years since that of racemic thalidomide was reported. This study revealed that 
crystallization from high polar methanol-water solution, in which hydrogen bonds are 
not generally formed, produces unsolvated (S)-thalidomide crystal and crystallization 
from nonpolar chloroform solution, in which thalidomide molecules exist in dynamic 
equilibrium of three isomeric dimers, produces solvated (S)-thalidomide crystal. Both 
unsolvated and solvated crystals are composed of two conformational isomers of 
(S)-thalidomide. The unsolvated crystals are formed with hydrogen bonded dimers 
consisting of pairs of these isomers, whereas the solvated crystals are formed with 
infinite hydrogen bonded chains consisting of alternately arranging conformational 
isomers.  
As future works, the capability for replacing solvent molecules at channel spaces 
with maintaining the host lattice of the clathrate structure in the solvated 
(S)-thalidomide crystals should be investigated. Achieving this property of solvated 
crystals will be expected for pharmaceutical application, particularly with water 
because only hydrates may be of practical use as drugs. 
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4. Investigation into the origin of differences in 
physicochemical properties between 
enantiomeric and racemic thalidomides 
 
 
 
4.1 Introduction 
 
Although a number of studies have reported bioactivities of thalidomide [1-8], only a 
few researches have reported its physicochemical properties. Racemic thalidomide is 
known to exhibit lower solubility and higher melting point than the enantiomers [1]. It is 
also known that the oral absorption of racemic thalidomide is slower than that of the 
enantiomers [2, 3]. However, the origin of differences in these physicochemical 
properties between enantiomeric and racemic thalidomides has not been investigated.  
As to chiral compounds, crystal structures of enantiomeric and racemic 
compounds are essentially different. Therefore, the idea of comparing crystal structures 
between an enantiomer and the racemate is significant for understanding differences in 
such physicochemical properties between them.  
Crystal structures of racemic thalidomide have been investigated since 1971 
[9].Two polymorphs of α and β forms are known in (RS)-thalidomide [10]. However, 
crystal structures between enantiomeric and racemic thalidomides have not been 
compared because even crystal structures of enantiomeric thalidomide have not been 
reported. 
To investigate the origin of differences in such physicochemical properties 
between (S)- and (RS)-thalidomides, this study, in this chapter, focuses on comparison 
of crystal structures between (S)- and (RS)-thalidomides. Crystallizations of (S)- and 
(RS)-thalidomide were performed with three different methods. The structures of 
(S)-thalidomide crystals investigated in chapter 3 are adopted for comparison with 
those of (RS)-thalidomide. The structures of (RS)-thalidomide crystals were 
investigated with X-ray diffractometry. Furthermore, structural stabilities of those 
crystals were evaluated with energy calculations. 
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4.2 Crystallization of (RS)-thalidomides 
 
4.2.1 Materials 
 
(RS)-thalidomides was purchased from Sigma-Aldrich, Inc. Methanol, chloroform, 
diethyl ether, and acetonitrile were purchased from Wako Pure Chemical Industries, 
Ltd. 
 
 
4.2.2 Experimental method 
 
As in the case of (S)-thalidomide, (RS)-thalidomide crystals were obtained with 
following three different crystallization methods: 
･ solvent evaporation technique from methanol-water solution; 
･ solvent evaporation technique from chloroform solution; 
･ vapor diffusion technique from chloroform solution. 
Detail procedures of crystallization are as follows. 
Crystallization procedure of (RS)-thalidomide with solvent evaporation technique 
from methanol-water solution was as follows: 
(1) (RS)-thalidomide powder (50 mg) was dissolved in 40 ml methanol-water (5:3). 
(2) The solution was evaporated for about 4 h at 50 °C. 
(3) The grown crystals floating on the solutions were filtered out. 
Crystallization procedure of (RS)-thalidomide with solvent evaporation technique from 
chloroform solution was as follows: 
(1) (RS)-thalidomide powder (6.28 mg) was dissolved in 4.8 ml chloroform. 
(2) The solution was evaporated in a few days at room temperature. 
(3) The grown crystals floating on the solutions were filtered out. 
Crystallization procedure of (RS)-thalidomide with vapor diffusion technique from 
chloroform solution was as follows: 
(1) (RS)-thalidomide powder (64.5 mg) was dissolved in 50 ml chloroform. 
(2) The inner vial containing 50 ml of this chloroform solution was put in the outer 
beaker with about 80 ml of diethyl ether. 
(3) This outer beaker was kept sealed for a few days at room temperature. 
(4) The grown crystals were filtered out. 
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4.2.3 Results 
 
Crystallization with solvent evaporation technique from methanol-water solution 
produced needle shaped crystals (II) (Figure 4.1(A)). To appropriately realize the same 
crystallization condition with (S)-thalidomide, (RS)-thalidomide was also crystallized 
in about 4 hours at temperatures around 50 °C. Crystallization with solvent evaporation 
technique from chloroform solution produced plate shaped crystals (IV) (Figure 
4.1(B)). Similarly, crystallization with vapor diffusion technique from chloroform 
solution also produced plate shaped crystals (VII) (Figure 4.1(C)). 
 
 
   
  
(A) (B) 
(C) 
Figure 4.1 Polarizing microscopic images of (RS)-thalidomide crystals obtained with (A) 
solvent evaporation technique from methanol-water solution (B) solvent evaporation technique 
from chloroform solution (C) vapor diffusion technique from chloroform solution. The scale 
bars represent 0.5 mm. 
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4.3 X-ray diffractometry on (RS)-thalidomide crystals 
 
4.3.1 Experimental method 
 
Crystals for X-ray diffractometry were carefully selected considering the points as 
mentioned in Section 3.3.1. X-ray diffraction data for all crystals (II, IV, and VII) 
were collected using a Rigaku RAXIS RAPID imaging plate detector with graphite 
monochromated Cu-Kα radiation. Crystal structures were solved by direct methods and 
refined by full-matrix least-squares on F
2 
[11]. Non-hydrogen atoms were refined with 
anisotropic displacement parameters, except for isotropically refined solvent molecules. 
Hydrogen atoms were refined using the riding model. 
 
 
4.3.2 Summary of results 
 
Crystal and structure refinement data combined with previous reports on α and β forms 
of (RS)-thalidomide are summarized in Table 4.1. To crystallographically determine the 
crystal structure, the result of single crystal X-ray diffractometry needs to fulfill the 
following requirements: 
 Rint < 0.1 
 R1 ≦ 0.1 
 wR2 < 0.25 
 -0.01 < Max Shift/Error < 0.01 
 0.8 ≦ Goodness of fit ≦ 2.0 
According to these requirements, crystal strictures of II, IV, and VII were 
crystallographically determined and completely refined. 
As a result of single crystal X-ray diffractometry, all of II, IV, and VII were 
determined as the isomorphic form with the previously reported α form of 
(RS)-thalidomide. Contrary to the case of (S)-thalidomide, all of II, IV, and VII are 
revealed to be unsolvated crystals of (RS)-thalidomide. To appropriately compare with 
the unsolvated (S)-thalidomide of I, this study focuses on II, which are crystallized 
with the corresponding method with I, as the crystal structure of α-(RS)-thalidomide.  
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 Previous report  
 α-form [9] β-form [10] II IV VII 
Empirical formula C13H10O4N2 C13H10O4N2 C13H10O4N2 C13H10O4N2 C13H10O4N2 
M (g mol-1) 258.23 258.23 258.23 258.23 258.23 
Temperature (K) NA 296(1) 93(1) 223(1) 173(1) 
Crystal system monoclinic monoclinic monoclinic monoclinic monoclinic 
Space group P21/n C2/c P21/n P21/n P21/n 
a (Å) 8.233(1) 20.741(2) 8.3156(3) 8.2668(3) 8.2855(3) 
b (Å) 10.070(2) 8.072(1) 9.9732(4) 10.0175(3) 10.0184(3) 
c (Å) 14.865(2) 14.216(1) 14.5740(5) 14.7749(5) 14.6698(5) 
β (°) 102.53(2) 102.78(1) 102.762(2) 102.603(2) 102.6511(19) 
V (Å3) 1203.0 2321. 1 1178.81(7) 1194.07(7) 1188.13(6) 
Z 4 8 4 4 4 
D (g cm-3) 1.426 1.48 1.455 1.436 1.444 
Reflection total/unique NA NA/2350 12229/2122 13090/2170 11767/2139 
Rint NA NA 0.064 0.038 0.089 
R1 [I > 2σ(I)] 0.053 0.057 0.0467 0.0447 0.0734 
wR2 (all data) NA 0.081 0.1212 0.1333 0.0830 
Max Shift/Error NA NA 0.000 0.000 0.000 
Goodness of fit NA NA 0.999 1.013 0.977 
  
Table 4.1 Crystal and structure refinement data for II, IV, and VII combined with those of 
previous reports on α and β forms of (RS)-thalidomide.  
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4.3.3 Crystal structures of (RS)-thalidomide 
 
The unit-cell structure of α-(RS)-thalidomide (II) is shown in Figure 4.2. The crystal 
structure of (RS)-thalidomide is formed with (R)- and (S)-thalidomide molecules in 
mirror conformation. In the α-(RS)-thalidomide crystal, pairs of (R)- and 
(S)-thalidomide molecules form the heterochiral dimers (Figure 4.3). Whereas, in the 
β-(RS)-thalidomide crystal, alternately arranged (R)- and (S)-thalidomide molecules 
form the infinite chain structure (Figure 4.4). 
 
 
 
 
  
Figure 4.2 The unit-cell structure of (RS)-thalidomide crystal drawn with thermal ellipsoids at 
50% probability level. Brown axes, green plane, and orange sphere represent 2-fold screw axes, 
mirror plane, and symmetry center, respectively. Color code: C: gray, N: blue, O: red, H: white. 
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Figure 4.4 Packing structure of the β-(RS)-thalidomide crystal along b axis [10]. 
Figure 4.3 Packing structure of the α-(RS)-thalidomide crystal along a axis. Green 
broken lines represent hydrogen bonds. Color code: C: gray, N: blue, O: red, H: white. 
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4.3.4 Comparison of crystal structures between (S)- and (RS)-thalidomides 
 
The crystal structures of unsolvated (S)-thalidomide (I) and α-(RS)-thalidomide (II) 
were compared in detail. Comparison of structural parameters between (S)-thalidomide 
(I) and (RS)-thalidomide (II) crystals is listed in Table 4.2. 
While the (RS)-thalidomide crystal consists of (R)- and (S)-thalidomide molecules 
in symmetrical conformations, the (S)-thalidomide crystal consists of two 
conformational isomers of (S)-thalidomide. To distinguish these four thalidomide 
molecules, namely (R)- and (S)-thalidomide molecules in the (RS)-thalidomide crystal 
and two conformational isomeric molecules of (S)-thalidomide in the (S)-thalidomide 
crystal, they are hereafter designated as RRS, SRS, S1, and S2, respectively. The 
conformation of SRS with atomic numbering of non-hydrogen atoms is shown in Figure 
4.5. In comparison of the conformational difference among three (S)-thalidomide 
molecules, SRS, S1, and S2, the dihedral angles between the mean plane composed of 
non-hydrogen atoms in the phthalimide ring and that in the glutarimide ring are 81.72° 
for SRS, 84.81° for S1, and 82.18° for S2, respectively. The packing structures of (S)- 
and (RS)-thalidomide crystal along a, b, and c axes are shown in Figures 4.6, 4.7, and 
4.8, respectively. The bond lengths and angles of the three (S)-thalidomide molecules 
are listed in Table 4.3 and Table 4.4, respectively. 
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 I II 
 (S)-thalidomide (RS)-thalidomide 
Crystal system monoclinic monoclinic 
Space group P21 P21/n 
a (Å) 8.40187 (15) 8.3156(3) 
b (Å) 10.02372 (18) 9.9732(4) 
c (Å) 14.4814 (7) 14.5740(5) 
β (°) 103.4938 (8) 102.762(2) 
V (Å3) 1185.93 (7) 1178.81(7) 
Z 4 4 
D (g cm-3) 1.446 1.455 
Figure 4.5 The configuration of SRS drawn with thermal ellipsoids at 50% probability level. 
Color code: C: gray, N: blue, O: red, H: white. 
Table 4.2 Comparison of structural parameters between I and II.  
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Figure 4.6 The packing structures of the (upper) (S)- and (lower) (RS)-thalidomide crystals 
along a axis. 
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Figure 4.7 The packing structures of the (upper) (S)- and (lower) (RS)-thalidomide crystals 
along b axis. 
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Figure 4.8 The packing structures of the (upper) (S)- and (lower) (RS)-thalidomide crystals 
along c axis. 
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Table 4.3 Comparison of bond lengths among S1, S2, and SRS molecules. Values in the 
parentheses represent standard deviations. 
Bond 
Length 
S1 (Å) S2 (Å) SRS (Å) 
O1-C1 1.205(2) 1.205(2) 1.215(2) 
O2-C8 1.218(3) 1.214(2) 1.212(2) 
N1-C1 1.413(3) 1.409(2) 1.395(2) 
N1-C8 1.400(2) 1.411(3) 1.403(2) 
C1-C2 1.492(2) 1.494(2) 1.487(2) 
C2-C3 1.379(3) 1.371(3) 1.372(2) 
C2-C7 1.385(3) 1.386(3) 1.392(3) 
C3-C4 1.392(3) 1.398(3) 1.395(2) 
C4-C5 1.395(3) 1.393(3) 1.387(3) 
C5-C6 1.393(3) 1.393(3) 1.394(2) 
C6-C7 1.380(3) 1.393(3) 1.375(2) 
C7-C8 1.480(3) 1.482(2) 1.486(2) 
    N1-C9 1.453(2) 1.450(2) 1.452(2) 
    O3-C10 1.210(2) 1.213(2) 1.216(2) 
O4-C11 1.223(2) 1.223(2) 1.226(2) 
N2-C10 1.379(2) 1.390(2) 1.378(2) 
N2-C11 1.382(3) 1.377(2) 1.378(2) 
C9-C10 1.521(3) 1.514(3) 1.516(3) 
C9-C13 1.518(3) 1.528(3) 1.516(3) 
C11-C12 1.501(3) 1.502(3) 1.500(3) 
C12-C13 1.524(3) 1.522(2) 1.508(2) 
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Table 4.4 Comparison of bond angles among S1, S2, and SRS molecules. Values in the 
parentheses represent standard deviations. 
Bond 
Angle 
S1 (°) S2 (°) SRS (°) 
C1-N1-C8 111.26(17) 111.66(16) 111.25(14) 
C1-N1-C9 125.14(18) 123.98(18) 124.33(14) 
C8-N1-C9 121.0(2) 122.09(18) 121.61(15) 
O1-C1-N1 125.2(2) 124.17(18) 124.56(16) 
O1-C1-C2 129.5(2) 130.2(2) 128.69(16) 
N1-C1-C2 105.35(19) 105.64(19) 106.75(15) 
C1-C2-C3 130.0(2) 130.7(2) 131.21(17) 
C1-C2-C7 108.2(2) 107.77(18) 107.4(15) 
C3-C2-C7 121.82(19) 121.5(2) 121.39(17) 
C2-C3-C4 116.7(2) 117.4(2) 117.35(18) 
C3-C4-C5 121.7(2) 121.4(2) 121.13(17) 
C4-C5-C6 120.8(2) 120.9(2) 121.25(18) 
C5-C6-C7 117.1(2) 116.9(2) 117.03(18) 
C2-C7-C6 121.8(2) 121.9(2) 121.85(16) 
C2-C7-C8 108.55(18) 109.33(19) 108.52(15) 
C6-C7-C8 129.6(2) 128.8(2) 129.61(17) 
O2-C8-N1 124.13(19) 124.54(18) 124.66(16) 
O2-C8-C7 129.8(2) 130.3(2) 129.48(17) 
N1-C8-C7 106.0(2) 105.20(19) 105.85(15) 
    N1-C9-C10 109.57(19) 108.92(18)  108.51(14) 
N1-C9-C13 115.0(2)  114.35(18) 114.88(18) 
C10-C9-C13 111.46(18) 111.00(19)  111.12(15) 
O3-C10-N2 121.8(2)  120.5(2) 120.77(16) 
O3-C10-C9 122.80(18) 124.15(18)  123.46(15) 
N2-C10-C9 115.30(19)  115.32(19) 115.7(15) 
C10-N2-C11 127.2(2)  126.59(19)  126.35(15) 
O4-C11-N2 119.5(2) 119.6(2)  119.46(17) 
O4-C11-C12 123.3(2)  122.7(2) 122.94(17) 
N2-C11-C12 117.22(18) 117.65(17)  117.59(15) 
C11-C12-C13 113.9(2)  113.9(2) 114.56(15) 
C9-C13-C12 108.9(2) 108.52(19)  109.41(18) 
  
Chapter 4 
79 
 
On one hand, pairs of RRS and SRS molecules form heterochiral dimers in the 
(RS)-thalidomide crystal. On the other hand, pairs of S1 and S2 molecules form 
homochiral dimers in the (S)-thalidomide crystal. Both the heterochiral dimer and the 
homochiral dimer are formed with two intermolecular hydrogen bonds. These 
hydrogen bonds link the glutarimide moieties of each molecule in a ring shape. The 
center of the hydrogen-bonded ring in heterochiral dimer is the symmetry center of the 
(RS)-thalidomide crystal. Therefore, the dihedral angle between the mean plane 
composed of N2, C11 and O4 in SRS and the corresponding plane in RRS is 0° as 
shown in Figure 4.9(A). In contrast, the dihedral angle between the mean plane 
composed of N2, C11 and O4 in S1 and that composed of N2‟, C11‟ and O4‟ in 
S2 ,where the primed numbers represent atoms of S2, is not 0° but 14.52° because S1 
and S2 are asymmetric as shown in Figure 4.9(B). 
 
 
 
 
  
Figure 4.9 Top and side views of hydrogen-bonded rings in (A) heterochiral dimer and (B) 
homochiral dimer. Blue and pink planes represent each mean plane, and only constituent atoms 
of the mean plane are drawn with thermal ellipsoids in side view. Green broken lines represent 
hydrogen bonds. Color code: C: gray, N: blue, O: red, H: white. 
(A) (B) 
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4.4 Evaluation of the structural stabilities with energy calculations 
 
4.4.1 Introduction 
 
The structural stability of the molecular crystal such as thalidomide crystals is closely 
related with intermolecular interaction in the crystal. The intermolecular interactions in 
thalidomide crystals originate from hydrogen bonds and Van der Waals Force. The 
hydrogen bonds are thought to main intermolecular interaction because hydrogen bond 
is much stronger than Van der Waals Force. Therefore, it is reasonable expectation that 
the differences in melting point between enantiomeric and racemic thalidomides are 
caused by the difference in structural stabilities between hydrogen-bonded rings in 
homochiral dimers and those in heterochiral dimers. On this hypothesis, this study 
evaluated the stabilities of hydrogen-bonded rings with calculation of the hydrogen 
bond energies. 
 
4.4.2 Experimental method 
 
Single-point energy of a molecule is the sum of the electron energy and the nuclear 
repulsion energy, and is obtainable from the density functional theory (DFT) calculation 
with a combination of a functional and a basis set [12]. This study calculated the 
single-point energies of monomers and dimers from the atomic coordinates in the crystal 
structures of (S)-thalidomide (I) and (RS)-thalidomide (II) using Gaussian
®
 03 program 
[13] based on DFT. The calculations were performed employing 12 practically used 
combinations of 3 functionals, B3LYP, B3PW91, and O3LYP, with 4 basis sets, 
6-31+G(d,p), 6-311++G(d,p), cc-pVDZ, and TZVP, respectively. 
This study estimated the hydrogen bond energy in the homochiral dimer (ΔEhomo) 
by subtracting the sum of the single-point energies of each monomer, which contains 
no contribution of inter-monomer interaction, from the single-point energy of the dimer, 
which contains the contribution of inter-monomer interaction, as follows: 
 2S1SSSohom EEEE  ,
 
(4.1)  
where ESS, ES1, and ES2 represent the single point energies of homochiral dimer, S1, and 
S2, respectively. Similarly, the hydrogen bond energy in the heterochiral dimer (ΔEhetero) 
was estimated as follows: 
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 SRRShetero EEEE  ,
 
(4.2)  
where ERS, ER, and ES represent the single point energies of heterochiral dimer, RRS, and 
SRS, respectively. 
These calculations assume the thalidomide monomer or dimer as alone in a 
vacuum, i.e. no neighboring molecules. Therefore, intermolecular interactions in 
crystalline state are not strictly reflected in these calculations. Moreover, to discuss the 
case in solution state, effect of solvents should additionally be included in calculation. 
Nevertheless, energy calculations for these dimer structures based on the crystal 
structures is significant for comparison between enantiomeric and racemic crystals 
composed with homochiral and heterochiral dimers, respectively. 
 
 
4.4.3 Results 
 
As shown in Table. 4.5, the hydrogen bond energies in heterochiral dimer are about 10% 
lower than that in homochiral dimer on all combinations of the functional and the basis 
set. This result suggests that the heterochiral dimer in the (RS)-thalidomide crystal is 
more stable than the homochiral dimer in (S)-thalidomide crystal. This is consistent with 
the differences of physicochemical properties that racemic thalidomide exhibits higher 
melting point than the enantiomeric thalidomide. 
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Table 4.5 Results of calculation in each combination of functionals and basis sets  ΔEhomo and 
ΔEhetero represent estimated hydrogen bond energy in homochiral and heterochiral dimers, 
respectively. 
Functional Basis set 
ΔEhomo 
(kcal mol
-1
) 
ΔEhetero 
(kcal mol
-1
) 
ΔEhomo-ΔEhetero 
(kcal mol
-1
) 
ΔEhetero / ΔEhomo 
B3LYP 6-31+G(d,p) -5.692864075 -6.448119450 0.755255374 1.132667031 
B3LYP 6-311++G(d,p) -5.885150557 -6.650696459 0.765545902 1.130080938 
B3LYP cc-pVDZ -8.950256935 -9.913402611 0.963145676 1.107610953 
B3LYP TZVP -5.903374060 -6.853759788 0.950385728 1.160990261 
      
B3PW91 6-31+G(d,p) -4.675627878 -5.450517397 0.774889519 1.165729510 
B3PW91 6-311++G(d,p) -4.954715866 -5.726484152 0.771768286 1.155764388 
B3PW91 cc-pVDZ -7.395916073 -8.356241552 0.960325479 1.129845373 
B3PW91 TZVP -4.800420692 -5.698508523 0.898087831 1.187085235 
      
O3LYP 6-31+G(d,p) -3.165314795 -3.852607125 0.687292330 1.217132378 
O3LYP 6-311++G(d,p) -3.159772631 -3.869748175 0.709975544 1.224691972 
O3LYP cc-pVDZ -6.391051226 -7.224241397 0.833190171 1.130368251 
O3LYP TZVP -3.286703998 -4.109936849 0.823232851 1.250473682 
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4.5 Conclusion 
 
In this chapter, this study focuses on comparison of crystal structures between (S)- and 
(RS)-thalidomides. The crystals obtained with three different methods were determined 
as the isomorphic with previously known α-form. Although the crystal structure of 
(RS)-thalidomide have been investigated, special attention on the heterochiral dimer 
formation in the crystal have not been paid. On the basis of the crystal structure of 
(S)-thalidomide determination in chapter 3, comparison of crystal structures between 
(S)- and (RS)-thalidomides reveals the main difference between (S)- and 
(RS)-thalidomide crystals is in the dimer structures: homochiral dimers in the 
(S)-thalidomide crystal and heterochiral dimers in the (RS)-thalidomide crystal. The 
comparison of these dimer structures suggested that the symmetric heterochiral dimers 
are more stable than the asymmetric homochiral dimers. The theoretical calculation 
based on the crystal structures revealed that the intermolecular energy of the 
heterochiral dimer is lower than that of the homochiral dimer. These results indicate 
that the known differences of physicochemical properties between racemic thalidomide 
and enantiomeric thalidomide originate from the stability difference of 
hydrogen-bonded rings between heterochiral dimers and homochiral dimers. 
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5. Overall conclusion 
 
 
 
5.1 Overall conclusion 
 
This study focused on the crystal structures of thalidomide. The principal results of this 
study are summarized in Table 5.1. Methods for crystallization of thalidomide were 
evaluated with consideration of possible multiple forms, i.e. polymorphs or solvates. 
The different crystallization methods produced crystals with different habits. Crystal 
structures and absolute configurations were determined except for the case of crystals 
obtained with solvent evaporation technique from chloroform solution of 
(S)-thalidomide. 
In the case of (S)-thalidomide, crystallization from high polar methanol-water 
solution, in which hydrogen bonds are not generally formed, produces unsolvated 
crystal, whereas crystallization from nonpolar chloroform solution, in which 
thalidomide molecules exist in dynamic equilibrium of three isomeric dimers, produces 
solvated crystal. Both unsolvated and solvated crystals are composed of two 
conformational isomers of (S)-thalidomide. The unsolvated crystals are formed with 
hydrogen bonded dimers consisting of pairs of these isomers, whereas the solvated 
crystals are formed with infinite hydrogen bonded chains consisting of alternately 
arranging conformational isomers (Figure 5.1). The clathrate structure in solvated 
crystals and non-stoichiometric inclusion of solvent molecules imply the capability for 
replacing solvent molecules at channel spaces with maintaining the host lattice of 
(S)-thalidomide. This property of solvated crystal will be expected for pharmaceutical 
application. 
In the case of (RS)-thalidomide, the corresponding three methods produced only 
unsolvated (RS)-thalidomide crystals. These crystals were determined as the 
isomorphic with previously known α-form. The comparison of homochiral dimers in 
(S)-thalidomide crystal and heterochiral dimers in (RS)-thalidomide crystal suggested 
that the symmetric heterochiral dimers are more stable than the asymmetric homochiral 
dimers. The theoretical calculation based on the crystal structures revealed that the 
intermolecular energy of the heterochiral dimer is lower than that of the homochiral 
dimer. These results indicate that the known differences of physicochemical properties 
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between racemic thalidomide and enantiomeric thalidomide originate from the stability 
difference of hydrogen-bonded rings between heterochiral dimers and homochiral 
dimers. 
 
 
Table 5.1 Comparison of solvate formation between (S)- and (RS)-thalidomide crystals 
obtained with three different methods. 
Solvent Technique 
Solute 
(S)-thalidomide (RS)-thalidomide 
methanol-water solvent evaporation unsolvate (I) unsolvate (II) 
chloroform solvent evaporation solvate (III) unsolvate (IV) 
chloroform-diethyl ether vapor diffusion solvate (V) / unsolvate (VI) unsolvate (VII) 
 
 
 
 
 
 
 
 
  
Figure 5.1 The structures of (A) hydrogen bonded dimer in unsolvated crystal of 
(S)-thalidomide and (B) hydrogen bonded chain in solvated crystal of (S)-thalidomide. Green 
broken lines represent hydrogen bonds. Color code: C: gray, N: blue, O: red, H: white, Cl: 
green. 
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The primary significance of this study is on the idea of comparison between an 
enantiomer and the racemate. Crystal structures of enantiomeric and racemic 
compounds are essentially different. However, almost no study concerning crystal of 
chiral compounds has focused on this idea. 
Although the crystal structure of (RS)-thalidomide have been investigated, special 
attention on the heterochiral dimer formation in the crystal have not been paid. In this 
study, determination of the crystal structure of (S)-thalidomide revealed not only the 
homochiral dimer structure in the crystal but also the main difference between (S)- and 
(RS)-thalidomide crystals being in the dimer structures. 
Furthermore, focusing on the result of III and IV, crystallization with solvent 
evaporation technique from chloroform solution demonstrated contrasting behavior at 
solvate formation: solvate of (S)-thalidomide and unsolvate of (RS)-thalidomide. This 
contrasting behavior should be significant, particularly for pharmaceutical compounds 
due to recent trends in the chiral drug development. 
 
 
5.2 Future works 
 
The exothermic peak without weight increase around 250 °C in TG-DTA on I indicated 
that the possible polymorphic transformation of (S)-thalidomide (Figure 5.2(A)). The 
previously study reported that β-(RS)-thalidomide is obtainable with melt of 
α-(RS)-thalidomide. Therefore, the result of TG-DTA suggests that (S)-thalidomide 
possibly transformed to the polymorph corresponding to β-(RS)-thalidomide. This 
possibility should be investigated for instance using X-ray diffractometry-differential 
scanning calorimetry. Moreover, the cause of the excess weight reduction around 
150 °C in TG-DTA on VI should also be investigated (Figure 5.2(B)). This result is 
strange because VI is determined as the unsolvated crystal with single crystal X-ray 
diffractometry. 
As to the solvated (S)-thalidomide crystals, the capability for replacing solvent 
molecules at channel spaces with maintaining the host lattice of the clathrate structure 
should be investigated. Achieving this property of solvated crystal will be expected for 
pharmaceutical application, particularly with water because only hydrates may be of 
practical use as drugs. 
Although solvated (RS)-thalidomide crystals were not obtained in this study, the 
possibility for obtaining solvated (RS)-thalidomide crystals should exist. Finding 
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crystallization methods for solvated (RS)-thalidomide and applying the methods for 
crystallization of (S)-thalidomide will provide interesting results, especially in terms of 
comparison with the results of this study. 
Furthermore, as the contrasting solvate formation of III and IV, contrasting 
behavior at polymorphs or solvates formation between an enantiomer and the racemate 
of other chiral compounds, particularly for pharmaceutical compounds, are of great 
interest.  
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Figure 5.2 TG-DTA curves of unsolvated (S)-thalidomide crystals (A) obtained with 
solvent evaporation technique from methanol-water solution (I) and (B) obtained with 
vapor diffusion technique from chloroform solution (VI). 
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 International Symposia 
 
“Chiroptical analysis of thalidomide and its hydrolytic products in solution”, 8th Joint 
Symposium between the University of Bonn and Waseda University, Tokyo, Oct. (2010) 
Yoshiyuki Ogino, Toshiya Suzuki, Masahito Tanaka, Toru Asahi. 
 
 
“Homochiral dimer in (S)-thalidomide crystal and heterochiral dimer in (RS)-thalidomide 
crystal”, 22nd International Symposium on Chirality, Sapporo, Jul. (2010) 
Toshiya Suzuki, Masahito Tanaka, Motoo Shiro, Norio Shibata, Tetsuya Osaka, Toru Asahi. 
 
 
“Spectroscopic investigation of collagen sheets with very high preferred orientation”, 22nd 
International Symposium on Chirality, Sapporo, Jul. (2010) 
Toru Asahi, Toshiya Suzuki, Yoshiyuki Ogino, Yuji Tanaka, Masayuki Yamato, Naoya 
Sawamura. 
 
 
“Temperature and pH dependence of thalidomide hydrolysis by chiroptical spectroscopy”, 
22nd International Symposium on Chirality, Sapporo, Jul. (2010) 
Yoshiyuki Ogino, Toshiya Suzuki, Masahito Tanaka, Toru Asahi. 
 
 
“Determination of absolute structure and optical rotator dispersion of γ-glycine”, 22nd 
International Symposium on Chirality, Sapporo, Jul. (2010) 
Kazuhiko Ishikawa, Toshiya Suzuki, Masahito Tanaka, Tsuneomi Kawasaki, Kenso Soai, 
Motoo Shiro, Toru Asahi. 
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"Asymmetric homochiral dimer in (S)-thalidomide crystal and symmetric heterochiral dimer in 
(RS)-thalidomide crystal", The 4th Global COE International Symposium on „Practical 
Chemical Wisdom‟,  okyo, Jan. (2010) 
Toshiya Suzuki, Masahito Tanaka, Motoo Shiro, Norio Shibata, Tetsuya Osaka, Toru Asahi. 
 
 
"Evaluation of stability difference between enantiomeric and racemic thalidomide crystals with 
X-ray structural analysis and energy calculation", 7th Joint Symposium between Waseda 
University and the University of Bonn, Bonn, Jan. (2010) 
Toshiya Suzuki, Masahito Tanaka, Norio Shibata, Tetsuya Osaka, Toru Asahi. 
 
 
“Measurements of chiroptical properties in condensed matters using the Generalized High 
Accuracy Universal Polarimeter”, The 1st International Symposium on Biomedical Science 
and Engineering, Tokyo, Jul. (2009) 
Toru Asahi, Toshiya Suzuki. 
 
 
“Comparison of chiroptical properties between solid and solution states”, 21st International 
Symposium on Chirality, Colorado, Jul. (2009) 
Toshiya Suzuki, Tetsuya Osaka, Toru Asahi. 
 
 
"Improvement of the Generalized High Accuracy Universal Polarimeter, G-HAUP", 
Waseda-Korea Universities' Joint Symposium on „Practical Chemical Wisdom‟,  okyo, Feb. 
(2009) 
Toshiya Suzuki, Toru Asahi. 
 
 
"General evaluation method of systematic errors in the Generalized High Accuracy Universal 
Polarimeter, G-HAUP", The 3rd Global COE International Symposium on „Practical Chemical 
Wisdom‟,  okyo, Jan. (2009) 
Toshiya Suzuki, Toru Asahi. 
 
 
“Novel evaluation method of systematic errors in the Generalized High Accuracy Universal 
Polarimeter, G-HAUP”, 20th International Symposium on Chirality, Geneva, Jul. (2008) 
Toshiya Suzuki, Toru Asahi. 
 
 
“Deposition of crystalline films of amino acid using a vacuum evaporation method”, 19th 
International Symposium on Chirality, San Diego, Jul. (2007) 
Toshiya Suzuki, Toru Asahi, Masahito Tanaka, Kuniaki Tatsuta, Tetsuya Osaka. 
 
 
“Anisotropic chiral films of isoleucine deposited with vacuum evaporation”, 18th International 
Symposium on Chirality, Busan, Jun. (2006) 
Toru Asahi, Toshiya Suzuki, Masahito Tanaka, Tetsuya Osaka, Hiroyuki Nishide, Kuniaki 
Tatsuta. 
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 Internal symposia 
 
“キラルおよびラセミ結晶中のサリドマイド分子の二量体構造”, 第４回分子科学討論
会, 大阪, 2010 年 9 月 
石川和彦，鈴木俊哉，田中真人，城始勇，柴田哲男，朝日透． 
 
 
“Evaluation of dimer structures in enantiomeric and racemic thalidomide crystals”, 
Symposium on Molecular Chirality 2010, 札幌, 2010 年 7 月 
鈴木俊哉，田中真人，城始勇，柴田哲男，逢坂哲彌，朝日透. 
 
 
“Chiroptical spectroscopic research on pH and temperature dependence of thalidomide 
hydrolysis”, Symposium on Molecular Chirality 2010, 札幌, 2010 年 7 月 
荻野禎之，鈴木俊哉，田中真人，朝日透. 
 
 
“Crystal structure and optical activity of γ-glycine crystal”, Symposium on Molecular Chirality 
2010, 札幌, 2010 年 7 月 
石川和彦，鈴木俊哉，田中真人，川崎常臣，硤合憲三，城始勇，朝日透. 
 
 
“Crystal structures of enantiomeric and racemic thalidomide”, 第 3 回東京女子医科大学・早
稲田大学 TWIns ジョイントシンポジウム, 東京, 2010 年 1 月 
朝日透，鈴木俊哉，田中真人，柴田哲男，逢坂哲彌． 
 
 
“サリドマイド結晶における分子の立体配置：対掌体結晶におけるホモキラル二量体と
ラセミ結晶におけるヘテロキラル二量体”, The Symposium on Chiral Science & 
Technology: Mesochemistry & Chemical Wisdom, 東京, 2009 年 9 月 
鈴木俊哉，柴田哲男，田中真人，逢坂哲彌，朝日透． 
 
 
“一般型高精度万能旋光計による異方性固体物質のキラル光学特性の測定”, モレキュ
ラー・キラリティー2009, 大阪, 2009 年 5 月 
鈴木俊哉，朝日透． 
 
 
“アミノ酸結晶性膜作製法の開発”, モレキュラー・キラリティー2007, 東京, 2007 年 5
月 
鈴木俊哉，田中真人，朝日透，竜田邦明，逢坂哲彌． 
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“アミノ酸結晶性膜の作製及びキラル光学的研究”, 第 54回応用物理学関係連合講演会, 
神奈川, 2007 年 3 月 
鈴木俊哉，籠宮功，中村尚倫，田中真人，朝日透，竜田邦明，逢坂哲彌． 
 
 
“Generalized High Accuracy Universal Polarimeterのナノ材料への応用”, 第15回有機結晶
シンポジウム, 愛媛, 2006 年 11 月 
朝日透，鈴木俊哉． 
 
 
“アミノ酸単結晶薄膜のキラル光学特性の評価”, 第 53 回応用物理学関係連合講演会, 
東京, 2006 年 3 月 
鈴木俊哉，籠宮功，中村尚倫，田中真人，朝日透，竜田邦明，逢坂哲彌． 
 
 
“アミノ酸薄膜のキラル光学的研究”, 第 66回応用物理学会学術講演会, 徳島, 2005 年 9
月 
鈴木俊哉，籠宮功，中村尚倫，田中真人，朝日透，竜田邦明，逢坂哲彌． 
 
 
 
 Workshops 
 
“G-HAUP を用いた有機/無機ハイブリッド層間化合物のキラル光学的研究”, 分子研研
究会, 愛知, 2006 年 2 月 
朝日透，中村尚倫，田中真人，籠宮功，鈴木俊哉． 
 
 
 
3. Patents 
 
“蒸着装置、蒸着方法、光学素子及びキラルセンサ”, PCT/JP2006/317644，朝日透，
逢坂哲彌，田中真人，鈴木俊哉，2006 年 9 月． 
 
 
